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Running title 
CCR2 signaling in cancer cells causes immune evasion  
Summary 
C-C chemokine receptor type 2 (CCR2) expressed on monocytes facilitates their recruitment to tumors. 
Here, CCR2 signaling in cancer cells is shown to suppress immune control of tumors, in part by reducing 
CD103+ dendritic cell recruitment.  
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ABSTRACT 
C-C chemokine receptor type 2 (CCR2) is expressed on monocytes and facilitates their recruitment to 
tumors. Though breast cancer cells also express CCR2, its functions in these cells are unclear. We found 
that Ccr2 deletion in cancer cells led to reduced tumor growth and ~2-fold longer survival in an orthotopic, 
isograft breast cancer mouse model. Deletion of Ccr2 in cancer cells resulted in multiple alterations 
associated with better immune control: increased infiltration and activation of cytotoxic T lymphocytes 
(CTLs) and CD103+ cross-presenting dendritic cells (DCs), as well as upregulation of MHC class I and 
downregulation of checkpoint regulator PD-L1 on the cancer cells. Pharmacological or genetic targeting 
of CCR2 increased cancer cell sensitivity to CTLs and enabled the cancer cells to induce DC maturation 
toward the CD103+ subtype. Consistently, Ccr2-/- cancer cells did not induce immune suppression in 
Batf3-/- mice lacking CD103+ DCs. Our results establish that CCR2 signaling in cancer cells can 
orchestrate suppression of the immune response. 
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INTRODUCTION  
Tumors escape immune control via multiple mechanisms (Dunn et al., 2002; Dunn et al., 2004). These 
mechanisms include cancer cell-intrinsic changes that alter how the cancer cell is recognized by the 
immune system and extrinsic changes that suppress immune cell activities. For example, cancer cells can 
intrinsically decrease the surface expression of major histocompatibility complex (MHC) class I, making 
them effectively invisible to cytotoxic T lymphocytes (CTLs) (Garrido et al., 2016). Moreover, cancer 
cells can upregulate programmed cell death ligand 1 (PD-L1/B7-H1), which binds the PD-1 receptor on 
activated T cells, resulting in T cell anergy, ultimately protecting cancer cells against T cell-mediated 
killing (Chen et al., 2016a). Extrinsic mechanisms include the downregulation of co-stimulatory molecules 
(e.g., CD86) on antigen-presenting cells; the secretion of cytokines that directly inhibit CTLs; and the 
recruitment of regulatory T cells and myeloid-derived suppressor cells (MDSCs) (Igney and Krammer, 
2002). In contrast, infiltration of CD103+ dendritic cells (DCs) in mice, phenotypically similar to CD141+ 
DCs in humans (Hildner et al., 2008), has emerged as a mechanism by which tumors may be kept under 
immune control. CD103+ DCs are highly efficient at acquiring and processing exogenous antigens, which 
they directly present on MHC class I molecules to CD8+ CTLs. Even a modest accumulation of CD103+ 
DCs in tumors has been associated with improved immune-mediated tumor control (Broz et al., 2014; 
Roberts et al., 2016). 
Chemokine receptors mediate the recruitment of immune cells to sites of inflammation and to 
tumors. C-C chemokine receptor type 2 (CCR2) is expressed by several bone marrow-derived cell types 
(including inflammatory monocytes, myeloid precursor cells, and immature DCs), as well as B and T 
lymphocytes (Lim et al., 2016). CCR2-expressing cells are recruited to sites of inflammation primarily by 
C-C chemokine ligand 2 (CCL2) (Deshmane et al., 2009), although other CCL family members also can 
activate CCR2. Chemotherapy treatment promotes CCR2-dependent infiltration of tumor-promoting 
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myeloid cells to murine mammary tumors (Nakasone et al., 2012), and CCL2/CCR2-mediated recruitment 
of CCR2+ inflammatory monocytes to the lung has been shown to promote breast cancer extravasation 
and metastasis in mouse models (Qian et al., 2011). Furthermore, elevated levels of CCL2 in tumors and 
in serum are associated with advanced disease and poor prognosis in breast carcinoma patients (Lebrecht 
et al., 2004; Lebrecht et al., 2001; Soria and Ben-Baruch, 2008). These findings have sparked interest in 
targeting the CCR2 pathway to modulate the innate immune response for therapeutic benefit in cancer. 
However, CCR2 is also expressed by breast cancer cells, and activation of CCR2 by CCL2 can induce 
cancer cell migration and survival through Smad3-, p42/44MAPK-, and Rho GTPase-mediated signaling 
(Fang et al., 2012). In vivo, the potential roles of CCR2 signaling in cancer cells have not been well 
investigated, largely because they were thought to be minor compared to the roles of CCR2 in myeloid 
cells.  
In this study, we report that CCR2 signaling in cancer cells plays a surprisingly major role in 
regulating the immune response to murine breast tumors. We show that CCR2 in cancer cells supports 
immune escape by inhibiting CD103+ DC infiltration and maturation and by suppressing cytotoxic T cell 
activity. CCR2 expression on cancer cells represents a previously uncharacterized mechanism for immune 
suppression. Thus, our data support the notion that the CCL2/CCR2 axis is an important immune 
modulatory pathway in cancer, utilized by both immune cells and cancer cells to orchestrate immune 
suppression.  
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RESULTS 
CCR2 in cancer cells promotes primary tumor growth in an orthotopic, isograft breast cancer 
mouse model 
To investigate the potential effects of CCR2 on breast tumor growth and metastasis, we crossed Ccr2-/- 
mice (Boring et al., 1997) with mouse mammary tumor virus - polyoma middle T (MMTV-PyMT) mice, 
a model of luminal B breast cancer (Guy et al., 1992; Lin et al., 2003). The Ccr2 genotype did not influence 
normal mammary gland development (Fig. S1a) or tumor onset (Fig. 1a); however, loss of even one allele 
of Ccr2 significantly reduced tumor growth rates (Fig. 1b). Consistently, survival time was significantly 
longer for the MMTV-PyMT;Ccr2-/- and MMTV-PyMT;Ccr2+/- mice compared to that of the MMTV-
PyMT;Ccr2+/+ mice (Fig. 1c). In addition, we noted that the tumors of MMTV-PyMT;Ccr2-/- and MMTV-
PyMT;Ccr2+/- mice were more cystic, with reduced solid areas, than those of MMTV-PyMT;Ccr2+/+ mice 
(Fig. S1b, c). 
The importance of CCR2 signaling for monocyte recruitment is well understood, but CCR2 is also 
expressed by human breast cancer cells (Fang et al., 2012). In accordance with this report, we detected 
Ccr2 mRNA and CCR2 protein in the cancer cells of the tumors developing in MMTV-PyMT;Ccr2+/+ 
mice (Fig. 1d, e), and using RNA fluorescence in situ hybridization (FISH), we demonstrated that Ccr2 
mRNA is expressed by Krt18-positive breast cancer cells (Fig. S1d). To determine the relative 
contributions of cancer cell vs. host CCR2 to tumor growth, we isolated primary cancer cells (purity >90%; 
Fig. S1e) from MMTV-PyMT;Ccr2+/+ and MMTV-PyMT;Ccr2-/- mice and transplanted them 
orthotopically to mammary glands of either Ccr2+/+ or Ccr2-/- syngeneic host mice (Fig. 1f). Loss of Ccr2 
in the host did not alter tumor growth, consistent with our previous report (Nakasone et al., 2012). 
However, loss of Ccr2 in cancer cells significantly reduced tumor growth rates, leading to ~2-fold longer 
survival (Fig. 1g, h). Ccr2 mRNA levels of Ccr2+/- cancer cells were lower than those of Ccr2+/+ cancer 
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cells (Fig. S1f), and tumors derived from Ccr2+/- cancer cells exhibited the same slow growth as tumors 
derived from Ccr2-/- cancer cells (Fig. S1g). This result suggests that a threshold level of CCR2 expression 
in MMTV-PyMT cancer cells regulates tumor growth. 
CCR2+ inflammatory monocytes can promote breast cancer metastasis (Muller et al., 2001; Qian 
et al., 2011). The overall metastatic burden in the lung—the primary site of metastasis in the MMTV-
PyMT model—was, however, very variable in MMTV-PyMT;Ccr2+/+ mice and was not significantly 
different from that of MMTV-PyMT;Ccr2-/- mice (Fig. S1h). There were also no significant differences 
in the number of metastatic foci (representing seeding density) related to the Ccr2 genotype (Fig. S1i). 
However, we found that the metastatic foci were larger in the lungs of MMTV-PyMT;Ccr2+/+ mice than 
in the lungs of MMTV-PyMT;Ccr2-/- mice (Fig. S1j), suggesting that CCR2 promotes the growth of 
secondary lesions. 
 
Ccr2 expression in cancer cells is associated with poor differentiation and reduced apoptosis 
sensitivity 
The tumors from transplanted Ccr2+/+ or Ccr2-/- cancer cells were markedly different at the histological 
level (Fig. 2a), similar to the autochthonous tumors in the MMTV-PyMT;Ccr2-/-  animals (Fig. S1b, c). 
The tumors originating from Ccr2+/+ cancer cells consisted entirely of microlobules composed of sheets 
of large, neoplastic epithelial cells. The microlobules were surrounded by small amounts of fibrovascular 
stroma containing dense collagen, which is characteristic of poorly differentiated MMTV-PyMT tumors. 
The neoplastic cells had round to oval nuclei, prominent nucleoli, scant cytoplasm, and indistinct cell 
borders, typical of undifferentiated cells. In contrast, the tumors originating from Ccr2-/- cancer cells were 
more differentiated. In many areas, the cancer cells contained lipid vacuoles of various sizes. These tumors 
also had large cystic areas lined by a single or double layer of small, polarized epithelial cells, and the 
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lumina were filled with proteinaceous secretions (Fig. 2a). Conversely, the tumors originating from Ccr2-
/- cancer cells had a reduced percentage of solid areas compared to those originating from Ccr2+/+ cancer 
cells (Fig. 2b).  
To understand why tumors from Ccr2-/- cancer cells grew slower than tumors from Ccr2+/+ cancer 
cells, we next examined the rates of proliferation and apoptosis in the tumors collected during the phase 
when Ccr2-/- tumors were growth-restricted, 5–6 weeks post-transplantation. There was no difference in 
proliferation as determined by nuclear Ki67 staining (Fig. 2c), and primary Ccr2+/+ and Ccr2-/- cancer 
cells also grew similarly in vitro (Fig. 2d). However, we found a higher percentage of cancer cells 
undergoing apoptosis in tumors from Ccr2-/- cancer cells than from Ccr2+/+ cancer cells (Fig. 2e). 
Furthermore, Ccr2-/- cancer cells were more sensitive to serum-free conditions (Fig. 2f), consistent with a 
previous study showing that CCR2 signaling can protect cancer cells from apoptosis induced by serum 
starvation (Fang et al., 2012).  
 
Ccr2-/- cancer cells have increased expression of interferon (IFN) response genes and of genes 
involved in MHC class I antigen presentation 
To determine which pathways in the Ccr2-/- cancer cells led to reduced tumor growth and increased cell 
death, we isolated cancer cells from Ccr2+/+ and Ccr2-/- transplanted tumors formed in wild-type hosts for 
equal amounts of time and performed transcriptome profiling by RNA-seq. Overall, 520 genes were 
differentially expressed (adjusted p-value <0.05), ~40% of which were upregulated in Ccr2-/- cancer cells 
compared to Ccr2+/+ cancer cells. Among the differentially expressed genes, we detected upregulation of 
MHC class I (H2-K1) and Tap1, two genes required for antigen presentation, and IFI27, an IFN response 
gene, in the Ccr2-/- cancer cells (Fig. 3a). Vimentin, which is found in poorly differentiated epithelial cells 
and in mesenchymal cells, was downregulated in Ccr2-/- cancer cells. This is consistent with a previous 
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study describing a mesenchymal and invasive phenotype in CCR2-expressing cancer cells (Hu et al., 
2019). Additionally, gene set enrichment analysis (GSEA) showed robust expression enrichment of the 
IFN- response hallmark gene set, which included genes involved in antigen processing and presentation, 
in Ccr2-/- cancer cells compared to Ccr2+/+ cancer cells (Fig. 3b). We also observed a pronounced luminal 
gene expression signature in the Ccr2-/- cancer cells (Fig. 3b), in agreement with the noted histological 
differences (Fig. 2a, b). Consistently, gene ontology (GO) term analysis revealed altered expression of 
pathways involved in 1) regulation of the adaptive immune system and in 2) response to immune-mediated 
cell killing (Fig. 3c). 
 
Cancer cell CCR2 promotes immune suppression  
The increased expression of genes associated with IFN response and antigen presentation, together with 
the prolonged growth delay and increased apoptosis in tumors from Ccr2-/- cancer cells, are consistent 
with an ongoing adaptive immune response in the tumors. We therefore determined whether there were 
any differences in the infiltrating immune cell populations by flow cytometry (for gating strategy, see Fig. 
S2). There were significantly more CD8+ CTLs and fewer CD4+ helper T cells in tumors from Ccr2-/- 
cancer cells than in tumors from Ccr2+/+ cancer cells (Fig. 4a), with no overall change in CD3+ T cell 
infiltration (Fig. S3a). Increased infiltration of CD8+ cells into tumors derived from Ccr2-/- cancer cells 
was also evident by immunofluorescence (Fig. 4b, c). PD-1 is an inhibitory checkpoint surface molecule 
expressed by activated CD8+ T cells (Chen et al., 2016a), and its expression was increased on CD8+ T 
cells from tumors from Ccr2-/- cancer cells (Fig. 4d). CTLs kill, in part, through the release of granzyme 
B, a process that requires lysosomal-associated membrane protein 1 (LAMP-1, also known as Cluster of 
Differentiation 107a, CD107a). In tumors from Ccr2-/- cancer cells, LAMP-1 was increased on the cell 
surface of CD8+ T cells (Fig. 4e), while granzyme B levels were reduced in CD8+ T cells (Fig. 4f), 
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indicating increased levels of prior CD8+ degranulation, and therefore cytotoxic activity. Regulatory T 
lymphocytes (CD4+FoxP3+ regulatory T cells), which are typically immunosuppressive, were more 
abundant in tumors from Ccr2-/- cancer cells (Fig. S3b).  
Tumors from Ccr2-/- cancer cells had multiple changes in the adaptive immune cell infiltrate, all 
consistent with an active immune response. Therefore, we tested whether an adaptive immune response 
contributed to the differences in growth rates between the Ccr2+/+ and Ccr2-/- tumors by transplanting 
cancer cells in parallel into T cell-deficient athymic (nude) or fully immunocompetent mice (Fig. 5a). In 
the immunocompetent hosts, tumors from Ccr2-/- cancer cells grew significantly slower than tumors from 
Ccr2+/+ cancer cells (Fig. 5b), as previously observed (Fig. 1g). In contrast, in the T cell-deficient hosts, 
the Ccr2-/- tumors grew at a similar rate as the Ccr2+/+ tumors (Fig. 5c). Consistently, tumors derived from 
Ccr2-/- cancer cells grew as fast as tumors derived from Ccr2+/+ cancer cells when CD8+ T cells were 
depleted from wild-type mice (Fig. S3c). Furthermore, in the T cell-deficient, athymic hosts, tumors from 
Ccr2-/- cancer cells no longer had more apoptotic cells than tumors from Ccr2+/+ cancer cells (Fig. 5d). 
Interestingly, the differentiated histological phenotype of the tumors from the Ccr2-/- cancer cells was 
maintained in the athymic mice (Fig. 5e, f). Thus, the histological differences were not the result of an 
altered adaptive immune response. Together, these data demonstrate that CCR2 expressed by cancer cells 
enables the tumors to escape the adaptive immune response.  
 We next speculated that the reduced growth of tumors from Ccr2-/- cancer cells could be a result 
of increased sensitivity to CTL-induced cell death, given that the Ccr2-/- cancer cells showed increased 
sensitivity to serum-free conditions and that the tumors grew normally when CD8+ T cells were depleted. 
To test this possibility, we used the MMTV-PyMT-chOVA model (Engelhardt et al., 2012), which is 
driven by the PyMT oncogene and co-expresses ovalbumin (OVA) as a model tumor antigen and mCherry 
for tracking. We generated MMTV-PyMT-chOVA;Ccr2+/+ and MMTV-PyMT-chOVA;Ccr2-/- mice and 
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found that similar to the MMTV-PyMT;Ccr2-/- tumors, the MMTV-PyMT-chOVA;Ccr2-/- tumors grew 
slower than MMTV-PyMT-chOVA;Ccr2+/+ tumors (Fig. 6a). When primary cancer cells were isolated 
and challenged with activated CTLs isolated from OT-1 mice (where T cells are engineered to recognize 
an OVA peptide presented by MHC class I), we found that MMTV-PyMT-chOVA;Ccr2-/- cancer cells 
were approximately twice as sensitive to CTLs as MMTV-PyMT-chOVA;Ccr2+/+ cancer cells (Fig. 6b). 
Upon treatment with a pharmacological inhibitor against CCR2 (RS 102895 hydrochloride (Mitchell et 
al., 2013)), the MMTV-PyMT-chOVA;Ccr2+/+ cancer cells became as sensitive to the OVA-specific CTLs 
as MMTV-PyMT-chOVA;Ccr2-/- cancer cells (Fig. 6c). The CCR2 inhibitor also increased specific 
cytolysis of OVA-expressing E0771 murine breast cancer cell line to the OVA-specific CTLs (Fig. S3d). 
In contrast, the CCR2 inhibitor had no effect on the specific cytotoxicity of the CTLs to the MMTV-
PyMT-chOVA;Ccr2-/- cancer cells (Fig. 6c).  
To test if Ccr2 expression in cancer cells also regulated sensitivity to CTLs in vivo, we measured 
the clonal expansion of T cells, an indicator of active proliferation of antigen-specific T cells, by 
sequencing the complementarity determining region 3 (CDR3) region of the T cell receptor (TCR) β chain. 
We found that clonality, a value corresponding to the extent of clonal expansion of T cells (Fig. 6d), was 
significantly higher in tumors from Ccr2-/- cancer cells than in tumors from Ccr2+/+ cancer cells (Fig. 6e), 
while there was no difference in clonality in the spleens of these groups of mice (Fig. 6f). These results 
suggested that tumor-recognizing CTLs were actively expanding due to antigen recognition in tumors 
from Ccr2-/- cancer cells, but that this expansion did not alter the systemic T cell response. Both Ccr2+/+ 
and Ccr2-/- cancer cells express the PyMT tumor antigen, and Ccr2+/+ cancer cells formed tumors at the 
same rate regardless of whether Ccr2+/+ or Ccr2-/- cancer cells were transplanted to the contralateral 
mammary gland (Fig. S3e). Together, these results suggest that the expression of CCR2 by cancer cells 
enables the tumors to establish a locally immune-suppressive microenvironment. 
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Cancer cell CCR2 alters MHC class I and PD-L1 expression  
CCR2 signaling can activate STAT transcription factors in cancer cells (Chen et al., 2015; Izumi et al., 
2013), and altered STAT1 or STAT3 signaling in cancer cells can in turn lead to a less immune-
suppressive microenvironment (Ahn et al., 2017; Jones et al., 2016). Therefore, we tested whether STAT 
activation was different between tumors from Ccr2+/+ and Ccr2-/- cancer cells. We found no consistent 
differences between the activation of STAT1, STAT3, or p65/RELA when whole tumor lysate was 
assayed by Western blot (Fig. 7a). By immunohistochemistry, we found that the tumors contained patches 
of cancer cells with high expression of phopho-STAT1, with more of these patches in the tumors from 
Ccr2-/- than from Ccr2+/+ cancer cells (Fig. 7b, c). No difference was observed for phospho-STAT3.  
We next sought to understand how CCR2 signaling in cancer cells resulted in more efficient 
immune suppression. RNA-seq analysis of the cancer cells showed increased expression of genes involved 
in antigen presentation in the Ccr2-/- tumors (Fig. 3a). Consistently, we found high levels of MHC class I 
expressed by cancer cells in MMTV-PyMT-chOVA; Ccr2-/- mice compared to the variable, low to 
intermediate, levels expressed by cancer cells in MMTV-PyMT-chOVA;Ccr2+/+ mice (Fig. 8a). 
Similarly, when cancer cells were transplanted to immunocompetent host mice, expression of MHC class 
I was higher by Ccr2-/- cancer cells than by Ccr2+/+ cancer cells, as shown by immunofluorescence (Fig. 
8b). However, in T cell-deficient, athymic host mice, MHC class I levels were similar on Ccr2+/+ and 
Ccr2-/- cancer cells (Fig. 8c). These data suggest that MHC class I expression is not directly regulated by 
CCR2 signaling in the cancer cells, but rather is regulated by the different immune responses between 
these tumors. 
PD-L1 is a potent suppressor of T cell activation and proliferation and is expressed on many types 
of cancer cells (Freeman et al., 2000). PD-L1 was significantly higher expressed on Ccr2+/+ cancer cells 
than on Ccr2-/- cancer cells (Fig. 8d). Since both MHC class I and PD-L1 are IFN-γ response genes, we 
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compared Ifn-g mRNA levels during the early tumor phase (three weeks post-transplantation) and found 
significantly higher levels of Ifn-g, as well as Cxcl9, in whole tumor lysate from tumors derived from 
Ccr2-/- compared to Ccr2+/+ cancer cells by RT-qPCR (Fig. S4a). RNA FISH revealed that the majority 
of the Ifn-g mRNA was expressed by infiltrating CD8+ T cells, and that Ifn-g levels were more variable 
during the growth-restricted phase of tumors than during the early tumor establishment phase (Fig. S4b, 
c, d). In vitro, recombinant IFN-γ treatment resulted in similar upregulation of Pd-l1 mRNA levels in 
Ccr2+/+ and Ccr2-/- cancer cells (Fig. 8e). Thus, our data suggest that Ccr2-/- cancer cells would be able to 
respond to increased IFN-γ levels in the tumor microenvironment by upregulating PD-L1. Since we see 
reduced PD-L1 expression on the Ccr2-/- cancer cells in vivo in the context of elevated Ifn-g, other factors 
must repress PD-L1 expression in vivo. Lastly, we tested whether PD-L1 blockade would alleviate 
immune suppression of the MMTV-PyMT tumors in vivo. However, anti-PD-L1 therapy had no 
significant effect on the growth of neither the Ccr2+/+ tumors nor the low PD-L1-expressing Ccr2-/- tumors 
(Fig. 8f). Thus, although reduced PD-L1 likely contributed to an increased sensitivity to CTLs in tumors 
from Ccr2-/- cancer cells, targeting PD-L1 expression was insufficient to reduce growth of the Ccr2+/+ 
tumors.  
 
Cancer cell CCR2 prevents the infiltration of cross-presenting CD103+ DCs 
We next examined the infiltration levels of immune populations that might be involved in immune 
suppression in the Ccr2+/+ tumors. There was no difference in CD11b+MHC class II+F4/80+ macrophages 
between tumors from Ccr2+/+ and Ccr2-/- cancer cells (Fig. S4e). There were, however, significantly fewer 
CD11b+MHC class II- myeloid cells in tumors from Ccr2-/- cancer cells (Fig. S4f). This population 
includes subsets of MDSCs, immature myeloid cells with immune-suppressive activity. Specifically, we 
found fewer granulocytes and granulocytic MDSCs (CD11b+CD11c-Ly6G+Ly6Clow cells) and more 
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inflammatory monocytes and myeloid MDSCs (CD11b+CD11c-Ly6G-Ly6Chigh cells) in tumors from 
Ccr2-/- cancer cells than from Ccr2+/+ cancer cells (Fig. S4g, h).  
Since DCs are critical for T cell activation, we performed immunofluorescence for CD11c+, a 
marker of DCs, and observed more infiltrating CD11c+ cells in the tumors derived from Ccr2-/- cancer 
cells than in those derived from Ccr2+/+ cancer cells (Fig. 9a). Furthermore, we found more than double 
the level of CD103+ DCs—a DC subtype that is very proficient in cross-presenting antigens to CD8+ T 
cells—in tumors from Ccr2-/- cancer cells than in those from Ccr2+/+ cancer cells (Fig. 9b). The number 
of CD103+ DCs was also increased in the draining lymph nodes (dLNs) for these tumors (Fig. 9c). A 
concern when using a transplant system to evaluate immune response is the potential for an immune 
reaction toward antigens on the transplanted cells. However, there were also more CD103+ DCs in the 
spontaneously developing tumors in MMTV-PyMT;Ccr2-/- mice than in MMTV-PyMT;Ccr2+/+ mice 
(Fig. S4i). Using RT-qPCR from whole tumor lysate and a panel of markers previously shown to be 
enriched in CD103+ DCs (Broz et al., 2014), we detected more mRNA for Cd11c and from activation 
markers, including Cd80, Cd86, and Il12b (Fig. 9d). Consistently, DCs in tumors from Ccr2-/- cancer cells 
displayed higher levels of CD86, a surface marker upregulated on activated DCs as determined by flow 
cytometry (Fig. 9e). The difference in CD103+ DC numbers was already apparent in the dLNs two days 
after injection of irradiated cancer cells into the mammary fat pad (Fig. 9f), suggesting a direct signal from 
the cancer cells. However, infiltration of CD103+ DCs was not increased in tumors from Ccr2-/- cancer 
cells in T cell-deficient, athymic mice (Fig. 9g). This finding suggests that a feedback loop between T 
cells and DCs is critical for CD103+ DC recruitment to the tumors.  
We next asked whether a factor secreted by Ccr2-/- cancer cells was responsible for DC maturation 
toward the CD103+ DC subtype. Indeed, when bone marrow-derived cells were cultured with conditioned 
medium from Ccr2-/- or Ccr2+/+ cancer cells, the total number of DCs was not different, but a significantly 
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higher percentage of CD11c+ cells were positive for CD103+ using conditioned medium from the Ccr2-
/- cells (Fig. 10a). Furthermore, the percentage of CD103+CD11c+ cells also increased when using 
conditioned medium from Ccr2+/+ cancer cells that had been treated with the CCR2 inhibitor (Fig. 10b), 
whereas adding the CCR2 inhibitor directly to the bone marrow-derived cultures did not by itself increase 
the percentage of CD103+ cells. Flt3 ligand and granulocyte-macrophage colony-stimulating factor (GM-
CSF) can both stimulate DC maturation toward the CD103+ subtype (Broz et al., 2014). Consistently, we 
found more mRNA for both Flt3l and Csf2 (coding for GM-CSF) in the tumors derived from Ccr2-/- cancer 
cells than from Ccr2+/+ cancer cells by RT-qPCR (Fig. 10c). Protein arrays showed that the levels of two 
CCR2 ligands, CCL2 and CCL12, and most other cytokines were similar between MMTV-PyMT;Ccr2+/+ 
and MMTV-PyMT;Ccr2-/- tumors (Fig. S5a), while IL-16 and granulocyte colony-stimulating factor (G-
CSF) were significantly lower in the MMTV-PyMT;Ccr2-/- tumors at the protein level. When secretions 
from overnight cultures of the cancer cells under serum-free conditions were analyzed, CCL2, CCL12, G-
CSF, and IL-16 were secreted to the same degree by Ccr2+/+ and Ccr2-/- cancer cells (Fig. S5b). Lastly, to 
test the importance of the CD103+ DCs in regulating an immune-controlling microenvironment, we 
transplanted Ccr2-/- and Ccr2+/+ cancer cells into Batf3-/- mice, which lack the basic leucine zipper 
transcription factor ATF-like 3 (BATF3) critical for CD103+ DC maturation. In these mice, the growth 
of Ccr2-/- cancer cell-derived tumors was restored to that of the Ccr2+/+ cancer cell-derived tumors (Fig. 
10d), and as expected, the percentage of infiltrating CD103+ DCs was significantly reduced (Fig. 10e). 
Furthermore, CD8+ T cell infiltration, as well as expression of CD107a and PD-1 by the T cells, were 
reduced in tumors derived from Ccr2-/- cancer cells transplanted into Batf3-/- mice (Fig. 10f, g, h). These 
findings support the notion that CD103+ DC and CD8+ T cells act together to regulate tumor immunity.  
 
DISCUSSION 
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The tumor-promoting effects of CCR2 are well-documented. However, they have mostly been attributed 
to CCR2-expressing immune and other host cells (Lim et al., 2016; Nakasone et al., 2012; Qian et al., 
2009; Qian et al., 2011; Wolf et al., 2012). Yet, CCR2 is also upregulated on breast cancer cells in a subset 
of breast cancers and this upregulation has been correlated with shortened survival (Labovsky et al., 2017). 
The expression of CCR2 by cancer cells has been proposed to promote tumor growth through increased 
motility and invasion, cell proliferation, and cell survival (Fang et al., 2012; Hu et al., 2019; Lu et al., 
2006). Here, we show that in the MMTV-PyMT mouse model, CCR2 signaling in cancer cells helps breast 
tumors establish a locally immune-suppressive microenvironment. Compared to tumors from Ccr2+/+ 
cancer cells, the tumors from Ccr2-/- cancer cells have higher infiltration of CD103+ DCs and activated 
CD8+ T cells, as well as lower infiltration of granulocytic MDSCs. Furthermore, the Ccr2-/- cancer cells 
have higher surface levels of MHC class I and lower levels of PD-L1. It is likely the combination of all of 
these changes that results in more effective immune surveillance of the Ccr2-/- cancer cells and reduced 
growth of tumors from these cells (Fig. 10i). To our knowledge, the ability of cancer cell CCR2 signaling 
to orchestrate tumor immune suppression has not previously been recognized.  
 Among the most notable changes in the tumor immune microenvironment caused by targeting 
cancer cell Ccr2 were the increased levels of both CD103+ DCs and CD8+ T cells in tumors, and the 
infiltration of these two cell populations was apparently connected. In athymic mice lacking mature CD8+ 
cells, the CD103+ DC infiltration was no longer elevated in tumors derived from Ccr2-/- cancer cells 
compared to those from Ccr2+/+ cancer cells. Conversely, in Batf3-/- mice, which lack the transcription 
factor BATF3 required for CD103+ DC development, CD8+ T cell infiltration was equally low for tumors 
from Ccr2+/+ and Ccr2-/- cancer cells. These observations are consistent with several other recent reports 
intimately linking the function of CD103+ DCs and CD8+ T cells in tumors. First, CD103+ DCs have 
been shown to secrete chemokines mediating T cell infiltration, including CXCL9 and -10 (de Mingo 
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Pulido et al., 2018; Spranger et al., 2017). Second, secretion of IL-12 from CD103+ DCs has been shown 
to stimulate CD8+ T cell function (Ruffell et al., 2014). Our data support these previous studies, showing 
not only a link between CD103+ DC and CD8+ T cell infiltration but also increased Cxcl9 and Il-12b 
mRNA in tumors derived from Ccr2-/- cancer cells. Altogether, these data support previous work showing 
that the regulation of CD103+ DC infiltration is a critical step in tumor immune surveillance (Broz et al., 
2014; Meyer et al., 2018; Roberts et al., 2016).  
 Our data suggest that CCR2 signaling regulates the secretion of a factor(s) from the cancer cells 
that affects the polarization of DCs to the CD103+ subtype. Several factors have been proposed to induce 
the polarization of CD103+ DCs, including Flt3L and GM-CSF (Mayer et al., 2014), and consistently, 
mRNA levels for both of these factors were higher in tumors from Ccr2-/- cancer cells than from Ccr2+/+ 
cancer cells. However, it is unclear if Flt3L and GM-CSF could be solely responsible for the difference in 
CD103+ DC infiltration between tumors from Ccr2+/+ or from Ccr2-/- cancer cells. A recent study reported 
that G-CSF secreted from MMTV-PyMT cancer cells can inhibit the differentiation of CD103+ DCs by 
downregulating interferon regulatory factor-8 in DC progenitors (Meyer et al., 2018). Interestingly, G-
CSF was reduced in MMTV-PyMT;Ccr2-/- tumors compared to MMTV-PyMT;Ccr2+/+ tumors, although 
secretion of G-CSF from isolated cancer cells was not reduced, suggesting that altered secretion is not a 
direct effect of CCR2 signaling in cancer cells.  
 Ccr2-/- cancer cells had distinct expression of a several genes, including many that were consistent 
with an IFN response. Among these, increased surface expression of MHC class I might explain why 
Ccr2-/- cancer cells are more sensitive to T cell-mediated killing than Ccr2+/+ cancer cells. However, since 
Ccr2+/+ cancer cells did not downregulate MHC class I in T cell-deficient, athymic mice, we speculate 
that MHC class I expression is not directly regulated by CCR2 signaling in the cancer cells. Rather, the 
altered expression of IFN response genes, including MHC class I, may be an indirect result of an immune 
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response in the tumors. Altogether, we propose that the cancer cells act on CD103+ DCs, leading to a 
feedback loop between CD103+ DCs and CD8+ T cells—two immune cell types with highly 
interconnected functions.  
 Our study has several translational implications. First, our findings provide a possible explanation 
as to why CCR2 overexpression in breast cancer cells is associated with shortened survival time 
(Labovsky et al., 2017). Second, results from an open-label, non-randomized phase I trial using a CCR2 
inhibitor against locally invasive pancreatic cancer suggest that the inhibitor enhanced chemotherapy 
response, reduced macrophage infiltration, and induced an anti-tumor adaptive immune response 
(Nywening et al., 2016). Our data suggest that the potential clinical benefits of CCR2 inhibitors might be 
caused by the combined inhibition of CCR2 signaling in both stromal and cancer cells. Interestingly, the 
loss of even one Ccr2 allele was sufficient to reduce tumor growth in our study, suggesting that partial 
inhibition of CCR2 could result in clinical benefit. It is unclear why Ccr2+/- cancer cells phenocopy the 
Ccr2-/- cancer cells, but this phenomenon could be due to reduced dimerization of CCR2 in Ccr2+/- cancer 
cells, consistent with a prior report (Rodriguez-Frade et al., 1999), or because surpassing a threshold level 
of CCR2 signaling is required to induce immune suppression. Finally, recombinant G-CSF and GM-CSF 
are routinely given with certain types of chemotherapy to support the bone marrow and reduce the risk of 
lethal febrile neutropenia (Mehta et al., 2015). Our data support prior studies suggesting that these 
cytokines play complex roles in regulating the immune response against tumors: they appear to have 
opposing effects on CD103+ DC differentiation, with GM-CSF stimulating CD103+ DC differentiation 
(Greter et al., 2012; Mayer et al., 2014) and G-CSF inhibiting it (Meyer et al., 2018). Although GM-CSF 
secretion in the tumor microenvironment potentially enhances immune responses against tumors by 
stimulating CD103+ DC differentiation, this cytokine can also mobilize immune-suppressive MDSCs, 
leading to suppression of an anti-tumor immune response (Bayne et al., 2012; Pylayeva-Gupta et al., 
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2012). Therefore, exploring other approaches than administration of recombinant GM-CSF and G-CSF to 
specifically boost CD103+ DC maturation could be an important future translational direction, and 
determining the exact mechanism that causes inhibition of cancer cell CCR2 signaling to promote CD103+ 
maturation may provide insights into how this process occurs. 
 We found that tumor onset was similar between MMTV-PyMT;Ccr2+/+ and MMTV-PyMT;Ccr2-
/- mice, while tumor growth was slower. These data are very similar to a prior report studying tumor growth 
in MTMV-Neu mice, where mice null for Ccl2, the ligand for CCR2, or mice treated with a 
pharmacological CCR2 inhibitor also had similar tumor onset yet reduced tumor growth rates, as did mice 
treated with a CCR2 inhibitor (Chen et al., 2016b). However, unexpectedly, MMTV-Neu mice lacking 
Ccr2 had accelerated, not reduced, tumor growth in this study, and the authors speculated that this could 
be due to abnormal differentiation of the monocytes in these mice or unintentional effects of the genetic 
targeting of Ccr2. There are several possible explanations for the difference between our result using 
MMTV-PyMT;Ccr2-/- mice and that of the MMTV-Neu;Ccr2-/- mice in the previous publication. First, 
tumors of MMTV-PyMT mice have more stromal components than tumors of MMTV-Neu mice. Second, 
the genetic background of the mice used in our experiments was C57BL/6, while it was BALB/c in the 
case of the MMTV-Neu model. Finally, our tumor transplantation experiments strongly suggest that the 
tumor growth phenotype in our model is caused by CCR2 expression by cancer cells, but it is not clear 
whether cancer cells in the MMTV-Neu model express CCR2 or whether the phenotype is due to effects 
from stromal cells.  
Despite the data suggesting that CCR2 inhibition has beneficial effects in cancer treatment, some 
studies have raised serious concerns about targeting the CCR2 ligand. Cessation of anti-CCL2 therapy 
resulted in increased pulmonary metastasis and decreased survival in a murine model of breast cancer, 
due to rapid mobilization of CCR2-expressing monocytes into circulation immediately upon cessation of 
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therapy (Bonapace et al., 2014). Therefore, CCR2 inhibition likely will have to be used in combination 
with other therapies to maximize the eradication of existing cancer cells and to avoid complications of 
discontinuing the inhibition. In summary, the divergent results across mouse models, genetic backgrounds, 
and variable experimental approaches to targeting CCL2 or CCR2 suggest that the effects of targeting this 
axis can depend on tumor subtype, genetic background, and cell types. 
 Our findings support the notion that the CCL2/CCR2 axis is an immune modulatory pathway in 
cancer, but with the added layer of complexity that cancer cells can hijack this chemokine receptor 
pathway to orchestrate immune suppression. In this study, we have focused on characterizing the cellular 
mechanisms responsible for the novel link between cancer cell CCR2 signaling and tumor immune 
suppression. Preclinical experiments suggest that CCR2 targeting strategies can have detrimental effects, 
including the promotion of metastasis (Bonapace et al., 2014; Li et al., 2013). Therefore, future work that 
identifies the precise mechanisms by which CCR2 signaling in cancer cells induces immune suppression 
in breast cancer may set the stage for developing novel immune modulatory therapies. There are ongoing 
clinical trials using pharmacological inhibitors of CCR2 in cancer patients, and our data suggest that the 
potential effects of inhibiting CCR2 signaling in cancer cells should be taken into account when 
interpreting the results from these trials. 
 
MATERIALS AND METHODS 
Mice 
Ccr2-/-, Batf3-/-, and OT-1 mice (all on a C57BL/6 background) were obtained from Jackson Laboratory 
(Bar Harbor, ME) and athymic (Nu/Nu) mice were obtained from Charles River Laboratory (Wilmington, 
MA). MMTV-PyMT mice (on C57BL/6 [referred to as BL/6] background) were bred at Cold Spring 
Harbor Laboratory (CSHL), and MMTV-PyMT-chOVA mice (Engelhardt et al., 2012) were a kind gift 
from Dr. Mathew Krummel (University of California, San Francisco). MMTV-PyMT and PyMT-chOVA 
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mice were intercrossed with Ccr2-/- mice. MMTV-PyMT;Ccr2+/+ and MMTV-PyMT;Ccr2-/- mice, and 
similarly MMTV-PyMT-chOVA;Ccr2+/+ and MMTV-PyMT-chOVA;Ccr2-/- mice, were from the same 
mouse colony (mice were littermates or their parents were littermates). All the BL/6 host mice were 
purchased from Jackson Laboratory. All animal experiments were approved by the Institutional Animal 
Care and Use Committee (IACUC) at CSHL and were conducted in accordance with the NIH Guide for 
the Care and Use of Laboratory Animals. 
 
Measurement of in vivo tumor growth and lung metastasis  
Tumor onset was determined by weekly palpation. Once a tumor was detected, its size was measured 
weekly by caliper, and tumor volume was calculated as (length x width2)/2. For primary tumor growth, 
mice were either sacrificed at end point, when tumors reached 20 mm or ulcerated (whichever came first) 
or at indicated time points (early phase: three weeks after transplantation; growth-restricted phase: 5–6 
weeks after transplantation). For the lung metastasis assay, mice were sacrificed at either of two IACUC-
approved endpoints (when tumors reached 25 mm or ulcerated). To determine metastatic burden, we 
adapted a previously published method (Nielsen et al., 2001). Briefly, lungs were placed in 4% 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS) in a vacuum desiccator for 1 h. The lungs 
remained in 4% PFA at 4°C for 48 h, followed by incubation in 20% sucrose in PBS at 4°C for 48 h. 
Lungs were embedded in Tissue-Tek O.C.T. compound embedding solution (Sakura, Torrance, CA). The 
blocks were then placed in a custom-made cutting chamber with razor blade inserts every 2 mm, and the 
block was cut into 2 mm sections. These sectioned lung pieces were then re-embedded in fresh O.C.T. to 
allow for cross-sectional cuts from the entire lung tissue. These cross-sections of the lungs were stained 
with H&E and scanned by an Aperio ScanScope® CS System (Leica Biosystems, Buffalo Grove, IL). 
The metastatic burden was calculated as the percentage of metastasis/lung area and the number of 
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foci/lung area, determined using Aperio eSlide Capture Devices software (Leica Biosystems). Histology 
was evaluated by pathologist J.E.W. and scored as percentage solid areas of tumors. 
 
Primary cancer cell isolation, culture, and transplantation  
Aged-matched virgin females (C57BL/6, Ccr2-/-, Batf3-/-, or Nu/Nu), 6-12 weeks of age, were used as 
hosts for transplantation. Cancer cells were isolated from 2-3 tumors, each one 8-10 mm in diameter, from 
MMTV-PyMT;Ccr2+/+ or MMTV-PyMT;Ccr2-/- mice. Tumors were mechanically dissociated and 
digested for 1 h with 1x collagenase/hyaluronidase (10X Solution, Stem Cell Technology, Cambridge, 
MA) containing DNase I (2 U/ml, Roche, Pleasanton, CA) in Roswell Park Memorial Institute (RPMI)-
1640 medium supplemented with 5% FBS (VWR Life Science Seradigm, Philadelphia, PA). Single cells 
and debris were removed from the resulting carcinoma organoid preparation by pulse centrifugation in 
HBSS supplemented with 5% FBS. Purified carcinoma organoids were dissociated into single cell 
suspension in 0.05% trypsin with 0.1% EDTA supplemented with 2 U/ml of DNase I (Roche) for 2-3 min. 
Single tumor cells were passed through a 100 μm cell strainer (BD Biosciences, San Jose, CA) and either 
plated in RPMI-1640 supplemented with 10% FBS for in vitro experiments or washed with PBS and 
immediately injected into the inguinal mammary glands of host mice (2.5×105 in 20 μl of 1:1 
PBS/Matrigel; Corning, Corning, NY).  
 To evaluate the effect of cancer cell Ccr2 on the anti-tumor immune response locally vs. 
systemically, contralateral transplantation was conducted with cancer cells with different Ccr2 genotypes 
transplanted into each inguinal mammary gland (2.5x105 in 20 l of 1:1 PBS:Matrigel; Corning, Corning, 
NY). Cancer cells were isolated as described above and both C57BL/6 and Ccr2-/- mice were used as hosts. 
 To transplant irradiated cancer cells, freshly isolated primary MMTV-PyMT;Ccr2+/+ or MMTV-
PyMT;Ccr2-/- cancer cells were plated in a 10 cm petri dish (2x106 per dish) in RPMI with 10% FBS, and 
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received 80 Gy of irradiation in the Gammacell 40 Exactor (Best Theratronics, Ottawa, Ontario, Canada). 
After irradiation, cancer cells were washed with PBS and injected into the inguinal mammary glands of 
host mice (2.5×105 in 20 μl of PBS). To generate cancer cell conditioned medium, primary cancer cells 
from either MMTV-PyMT;Ccr2+/+ or MMTV-PyMT;Ccr2-/- tumors were plated in a 10 cm dish (2x106 
per dish) in DMEM/F12 medium plus 10% FBS, 1% penicillin/streptomycin, with or without CCR2 
antagonist (RS504393, 10 M, Sigma-Aldrich, St. Louis, MO) for two days. The conditioned medium 
was collected and centrifuged at 300 x g for 10 min, and the supernatant was used in experiments.  
 
In vivo antibody treatment  
Tumor cells from MMTV-PyMT;Ccr2+/+ or MMTV-PyMT;Ccr2-/- mice were transplanted as described 
above. For anti-PD-L1 treatment, on days 15, 18, 21, and 24 after transplantation (after tumors had 
formed), mice received 200 μg of anti-PD-L1 antibody by intraperitoneal injection (Clone 10F.9G2; Bio 
X Cell, West Lebanon, NH) or control rat IgG2b antibody (Bio X Cell) (Winograd et al., 2015). For CD8+ 
T cell depletion, mice were injected intraperitoneally with 200 g of anti-CD8a antibody (Clone 2.43; 
BE0061; Bio X Cell, West Lebanon, NH) or control rat IgG2b antibody (Clone LTF-2; BE0090; 
Bio X Cell, West Lebanon, NH) every three days starting from day 0 and until day 30. Tumor size was 
measured biweekly, and mice were sacrificed at IACUC-approved endpoint. 
 
Flow cytometry  
Tumors were harvested and mechanically dissociated for 30 min with collagenase D (2 mg/ml; Sigma-
Aldrich) and DNase I (4 U/ml; Roche) in RPMI. For flow cytometry of cells from lymph nodes, the lymph 
nodes were forced through a 100 m cell strainer (BD Biosciences), and flow-through cells were collected 
for experiments. Cells were resuspended in 1 x HBSS supplemented with 0.5% BSA and centrifuged at 
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300 x g. The cell suspension was filtered through a 70 μm cell strainer, and red blood cells were lysed 
using red blood cell lysing buffer (Sigma-Aldrich) for 1 min at room temperature.  
 For flow cytometry staining, cells (1×106) were incubated with mouse Fc Block (clone 2.4G2, BD 
Biosciences) for 10 min on ice, and then stained with the appropriate antibodies to surface markers at 4°C 
for 30 min in the dark or permeabilized and stained with intracellular antibodies overnight (see below for 
antibodies). Cell viability stain Zombie Red (BioLegend, San Diego, CA) was used to differentiate 
between dead and live cells. The stained populations were analyzed using an LSR II flow cytometer (BD, 
Franklin Lakes, NJ) (see Fig. S2 for gating strategies) and FlowJo software (BD, Version 10). Antibodies: 
CD45-eFluor 450 (Clone 30-F11), CD11c-PE-Cy7 (Clone N418), MHC II (I-A/I-E)-APC-eFlour780 
(Clone M5/114.15.2), CD103-FITC (Clone 2E7), CD274 (B7-H1, PD-L1)-PE-Cy7 (Clone MIH5), CD3-
FITC (Clone 17A2), CD8-eFluor450 (Clone 53-6.7), CD107a (LAMP-1)-PE (Clone 1D4B), IFN-γ-PE 
(Clone XMG1.2), Granzyme B-FITC (Clone NGZB), γδ TCR-PE-Cy5 (Clone GL3), and FoxP3-PE 
(Clone NRRF-30) all from eBioscience (Waltham, MA); CD4-PerCP-Cy5.5 (Clone BM9), CD69-PE 
(Clone H1.2F3), F4/80-PerCP-Cy5.5 (Clone BM9), MHC I (H-2)-PE (Clone M1/42), CD326 (EpCAM)-
APC (Clone G8.8), and CD86-BV510 (Clone GL-1) all from BioLegend; CD45-APC (Clone 30-F11), 
Ly6G-FITC (Clone 1A8), and CD11b-PE (Clone M1/70) from BD Pharmingen; EpCAM-APC (Clone 
CI:A3-1, AbD Serotec [Hercules, CA]) and CCR2-flourescein (Clone 475301, R&D Systems). Prior to 
Granzyme B staining, cells were incubated for 2 h with Brefeldin A (Sigma-Aldrich, #B6542).  
 
Cytokine array 
Tumors (8-10 mm in diameter) were isolated from MMTV-PyMT;Ccr2+/+ and MMTV-PyMT;Ccr2-/- 
mice and immediately snap-frozen in liquid nitrogen. They were then homogenized in PBS with the 
addition of protease inhibitors (Promega, Madison, WI). Proteome Profiler Mouse Cytokine Array Kit, 
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Panel A (R&D Systems) was used according to the manufacturer’s instructions. Films were scanned, and 
spots were analyzed using ImageJ software. 
 
MTS assay 
Proliferation of cancer cells isolated from MMTV-PyMT;Ccr2+/+ and MMTV-PyMT;Ccr2-/- mice was 
measured using the CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS; Promega) 
according to the manufacturer’s instructions. In this assay, the MTS tetrazolium compound (Owen’s 
reagent) was bioreduced by metabolically active cells into a colored formazan product. The quantity of 
formazan product was measured in a 96-well plate by absorbance at 490 nm.  
 
RNA purification and real-time quantitative PCR (RT-qPCR) analysis 
Total RNA from cancer cells (cultured 48 hours in RPMI supplemented with 10% FBS) or primary tumors 
was extracted using an RNAeasy kit (Qiagen, Germantown, MD), following the manufacturer’s 
instructions. RNA was quantified using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA). Reverse transcription was performed with an ImProm-II Reverse Transcription System 
(Promega) for the cancer cells, or the RevertAid First Strand cDNA Synthesis system (Thermo, K1622) 
for the primary tumors, with the following cycling conditions: 5 min at 70°C, 10 min at 4°C, 5 min at 
25°C, 60 min at 42°C, and 15 sec at 70°C using 1 g of total RNA extract for 20 μL of final volume. RT-
qPCR analysis was performed using a TaqMan gene expression assay (Thermo Fisher Scientific) with the 
following specific primers: Ccr2: Mm00438270_m1; Pd-l1: Mm00452054_m1; Cd8a: Mm01182107_g1; 
Ifn-g: mm01168134_m1; Pd-1: mm01285676_m1; Gzmb: mm00502528_m1; Ctla4: mm00486849_m1; 
Prf1: mm00812512_m1; Clec9a: mm00554956_m1; Cxcl9: mm00434946_m1; Cxcl10: 
mm00445235_m1; Cxcr3: mm00438259_m1; Cxcr4: Mm01996749_s1; Cd11c: mm00498698_m1; 
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Cd40: mm00441891_m1; Cd80: mm00711660_m1; Cd86: mm00444543_m1; Ccl5: mm01302427_m1; 
Il-12b: mm01288989_m1; Tim3: mm00454540_m1; Csf2: mm01290062_m1; Flt3l: mm00442801_m1; 
Flt3: mm00439016_m1; Ccl2: mm00441242_m1; Csf3: mm00438334_m1; Csf1: mm00432686_m1 and 
Tbp: mm01277042_m1. For cancer cells, RT-qPCR was performed on three independently isolated cancer 
cell populations and in triplicate for each sample. To determine the effects of IFN- on Pd-l1 expression, 
cancer cells were cultured with indicated concentration of IFN- (R&D systems, catalogue #485-MI-100) 
for 48 h before isolation of RNA. For tumor samples, RT-qPCR was performed on at least five primary 
tumors from different mice and in triplicate for each sample. Relative quantitation was performed with 
the 2(−∆∆CT) method using -Actin or Tbp expression for normalization and MMTV-PyMT;Ccr2+/+ cancer 
cells or tumor samples as a reference sample.  
 
RNA in situ hybridization 
RNA in situ hybridization (ISH) was performed on PFA-fixed paraffin-embedded tissue sections using an 
RNAscope Chromogenic 2.0 Detection Kit (Advanced Cell Diagnostics [ACD], Inc., Newark, CA). A 
Ccr2 probe was custom-designed by ACD, Inc. (Catalog number 436261-C2) and used according to the 
manufacturer’s instructions. We confirmed that no signal was found with the probe using Ccr2-/- tissues. 
RNA fluorescent ISH (FISH) for Ccr2, Krt8, Cd8a, and Ifn-g was performed on fresh frozen tissue 
sections using an RNAscope Fluorescent Multiplex Assay Kit (Advanced Cell Diagnostics 
[ACD], Inc., Newark, CA) with the following probes (by ACD): Ccr2: 436261-C2; Krt18: 424531-C1; 
Cd8a: 401681-C1; and Ifn-g: 311391-C3) and used according to the manufacturer’s instructions. For 
Ccr2 RNA FISH, we confirmed that no signal was found with the probe using Ccr2-/- tissues.  
  
Hematoxylin and eosin staining 
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PFA-fixed paraffin-embedded tissue sections were deparaffinized and rehydrated following standard 
protocols, stained with Gill’s Hematoxylin (Thermo Fisher Scientific, REF6765008) for 3 min, washed in 
tap water, rinsed with Nu-Clear II (Thermo Fisher Scientific, REF6769009), and then rinsed again first 
with tap water and then with Bluing Reagent (Thermo Fisher Scientific, REF 6769001). Slides were then 
stained with eosin (Sigma, HT110180), dehydrated following standard protocols, air-dried, and mounted 
with Cytoseal 60 (Thermo Fisher Scientific, Catalog number 831016).  
 
Immunofluorescence staining 
To stain for cytokeratin 5 and cytokeratin 8, paraffin sections were deparaffinized and rehydrated, and 
antigen retrieval was carried out by boiling slides in Tris EDTA buffer (10 mM Tris Base, 1 mM EDTA, 
pH 9.0) for 6 min in a pressure cooker. The slides were blocked with  1x blocking buffer (PBS containing 
2.5% BSA and 5% goat serum) and Fc receptor blocker (Innovex Biosciences, Richmond, CA), before 
incubating with anti-cytokeratin 5-Alexa Fluor 488 conjugated antibody (ab193894; 1:200 dilution; 
Abcam) and anti-Cytokeratin 8-Alexa Fluor 405 conjugated antibody (ab210139; 1:200 dilution; Abcam) 
overnight at 4°C. Sections were counterstained with ToPro-3 (1:1000 dilution; Life Technologies). 
For all other stainings, frozen tissue sections were incubated with 1x blocking buffer (5% goat 
serum, 2.5% BSA in PBS) and Fc receptor blocker (Innovex Biosciences). Sections were incubated with 
rabbit anti-CD3 polyclonal antibody (1:500 dilution; Abcam, Cambridge, MA), rat anti-MHC class I 
monoclonal antibody (Clone ER-HR52, 1:100 dilution; Abcam), rat anti-PyMT antibody (Ab15085, 
1:200; Abcam), rabbit anti-cleaved caspase-3 (Asp175) (D3E9) (#9579; 1:200 dilution; Cell Signaling 
Technology), anti-CD8a-Alexa Fluor 488 (Clone 5.3-6.7), anti-CD11c-Alexa Fluor 488 (Clone N418), or 
anti-CD326 (EpCAM)-APC (Clone G8.8) in 0.5 x blocking buffer overnight at 4°C. Secondary antibodies 
(not used for primary antibodies conjugated to Alexa-Fluor 488) anti-rabbit-Alexa568, or anti-rat-
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Alexa568 (1:150 dilution; Life Technologies) were used for detection, and sections were counterstained 
with DAPI (1:200 dilution; Life Technologies). Images were collected at 40x magnification using a Leica 
SP8 confocal or an AX10 microscope and an AxioCam HRc camera (Zeiss, Thornwood, NY) and were 
analyzed using Volocity software (Version 6.3.0, PerkinElmer, Waltham, MA).  
 
Immunohistochemistry and terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) staining 
Sections were deparaffinized and rehydrated. For phospho-STAT3 and Ki67 staining, antigen retrieval 
was carried out by boiling slides in 10 mM sodium citrate buffer (pH 6.0) for 6 min in a pressure cooker, 
while for phospho-STAT1 staining, antigen retrieval was done in Tris EDTA buffer (10 mM Tris Base, 1 
mM EDTA, pH 9.0). The slides were blocked with 3% hydrogen peroxide, 1x blocking buffer (PBS 
containing 2.5% BSA and 5% goat serum), Fc receptor blocker (Innovex Biosciences), and finally 
avidin/biotin blocking buffer (Vector Laboratories, Burlingame, CA, SP-2001). Slides were then 
incubated with primary antibodies overnight at 4°C in 0.5x blocking buffer: rabbit anti-Ki67/MK167 
(1:1,000 dilution; Novus International, Saint Charles, MO, NB110-89717), rabbit anti-phospho-STAT1 
(1:200 dilution; Cell Signaling Technology, Danvers, MA), or rabbit anti-phospho-STAT3 (1:500 
dilution; Cell Signaling Technology). After incubating with secondary biotinylated goat anti-rabbit IgG 
antibody (1:500, Vector Laboratories, BA-1000) for 1 h at room temperature, slides were incubated with 
avidin-conjugated horseradish peroxidase (Vector Laboratories, PK-6100) for 30 min, and the signals 
were detected by a DAB (3,3’-Diaminobenzidine) substrate kit (Vector Laboratories, SK-4100). Lastly, 
sections were counter-stained with hematoxylin. TUNEL staining was performed on deparaffinized 
sections to detect late-stage apoptotic cells using the ApopTag peroxidase in situ apoptosis detection kit 
(Millipore, Burlington, MA), according to the manufacturer’s instructions. Images were scanned by an 
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Aperio ScanScope® CS System (Leica Biosystems), and positive nuclei were counted using Aperio eSlide 
Capture Devices software (Leica Biosystems). 
 
ImmunoSEQ 
Tumors from Ccr2+/+ and Ccr2-/- transplants were isolated and immediately placed in liquid nitrogen for 
shipment. Amplification and sequencing were performed on the immunoSEQ platform (Adaptive 
Biotechnologies, Seattle, WA) using a multiplex PCR-based assay that exclusively targets rearranged T 
cell receptor genes. Sequencing data were analyzed using immunoSEQ Analyzer software. Shannon’s 
Entropy (H), a measure of the richness and uniformity of the frequency of the T cell receptor repertoire 
distribution, was defined as: 
  
Where N equals the number of unique clones and Pi the frequency of clones. To account for variation in 
sequencing depth, entropy was normalized by its maximum value (Hmax): 
  
Clonality is defined as C = 1 - HN. (Sherwood et al., 2013). Sequencing files are available from the 
Adaptive Biotechnologies immunoSEQ web site. 
 
Transcriptional profiling and bioinformatics analysis 
Ccr2+/+ or Ccr2-/- cancer cells were isolated from tumors and sorted as EpCAM+CD45-CD31- live cells 
(using 7-AAD Viability Staining Solution, Thermo Fisher Scientific) four weeks after orthotopic 
transplantation into the mammary glands of wild-type C57BL/6 mice. Total cancer cell RNA was 
extracted using a TRIzol extraction protocol. cDNA libraries were prepared using the Ovation® RNA-Seq 
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System V2 (NuGEN Technologies, San Carlos, CA) according to the manufacturer’s protocol and 
sequenced using a NextSeq 500 instrument (Illumina, San Diego, CA) to obtain 388 million 76 bp single-
end reads. Reads were mapped to the reference mm9 mouse genome using Spliced Transcripts Alignment 
to a Reference (STAR)	(Dobin et al., 2013) and were determined using HTSeq (Anders et al., 2015). 
Differential gene expression analysis was performed using DESeq2	 (Love et al., 2014) with a false 
discovery rate cutoff of 5%. Hierarchical clustering was performed by sample and gene using normalized 
and log2-transformed gene expression values of differentially expressed genes. All of the analyses 
described above were performed on the Bioinformatics Shared Resource Galaxy server at CSHL. Gene 
set enrichment analysis (Subramanian et al., 2005) was performed on a pre-ranked gene list sorted by 
log2FoldChange value against v5.1 Hallmark gene sets using default parameters. Gene ontology term 
enrichment analysis was performed using GOrilla PANTHER (Eden et al., 2009). 
 
Bone marrow-derived dendritic cell (BMDC) isolation, culture, and activation 
BMDCs were isolated and cultured as previously described (Inaba et al., 1992). Briefly, bone marrow was 
obtained from female C57BL/6 mice by flushing the femur and tibia with 2 ml of HBSS using a 1 mL 
insulin syringe with a 29G × ½ needle. The cells were washed with HBSS twice by centrifugation at 250 
x g for 8 min and then suspended in BMDC culture medium (RPMI-1640 medium [Thermo Fisher 
Scientific] containing 10% FBS, 20 ng/ml recombinant mouse GM-CSF [BioLegend], 50 units/ml 
penicillin, and 50 μg/ml streptomycin). The cells were then plated in 10 cm culture plates (2×106 cells per 
petri dish) and kept at 37°C in a 5% CO2 incubator for three days, then split at day 4 into two plates. For 
activation of BMDCs with cancer cell conditioned medium, the non-attached BMDCs were harvested at 
day 6 by gently pipetting the cultures with medium. This BMDC population was then rinsed three times 
in HBSS and suspended in a) culture medium, b) conditioned medium from MMTV-PyMT;Ccr2-/- or 
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MMTV-PyMT;Ccr2+/+ cancer cells, or c) conditioned medium from MMTV-PyMT;Ccr2+/+ cancer cells 
cultured (either with or without CCR2 antagonist (RS504393, 10 M, Sigma-Aldrich). After incubation 
with conditioned medium for 24 h, non-adherent BMDCs were harvested for flow cytometry. 
 
Chromium release assay 
Cytotoxic CD8+ T cells were isolated from spleens of OT-I transgenic mice by magnetic labeling and 
separation (Miltenyi Biotec, Cambridge, MA). Briefly, the spleen was forced through a 100 m cell 
strainer (BD Biosciences), and flow-through cells were collected. After lysing red blood cells, the 
splenocytes were washed and incubated with CD8a+ T Cell Biotin-Antibody Cocktail, mouse (Miltenyi 
Biotec) at 4°C for 5 min, followed by incubating with anti-Biotin microbeads (Miltenyi Biotec) at 4°C for 
10 min. The cell suspension was applied to an LS column (Miltenyi Biotec) in a magnetic field, and the 
flow-through (negatively selected) CD8+ T cells were collected. The isolated CD8+ T cells were cultured 
on plates coated with anti-mouse-CD3 (BioLegend) in RPMI-1640 containing 10% FBS, 50 M of -
mercaptoethanol, 20 ng/ml mouse IL-2, 2 ng/ml mouse IL-7, and 1% penicillin/streptomycin for 6-9 days. 
Primary cancer cells were isolated as described above from MMTV-PyMT-chOVA;Ccr2+/+ or MMTV-
PyMT-chOVA;Ccr2-/- mice and cultured overnight with or without CCR2 antagonist (10 M,Sigma 
RS504393) and OVA peptides (1 g/ml) in DMEM/F12 medium with 10% FBS. The E0771 cancer cell 
line was infected with lentivirus expressing luciferase and OVA SIINFEKL peptide fused to the C-
terminus of eGFP. Transduced cells were sorted by flow cytometry for eGFP-positive cells. For chromium 
(51Cr) release assay, cancer cells (1,000 per well) were incubated with 50 l of 51Cr solution (activity 1 
mCi/ml, PerkinElmer) plus 50 l of RPMI medium with 10% FBS for 2 h at 37°C. After rinsing the cells 
three times with RPMI plus 10% FBS, 50 l of cancer cells (1,000) were plated into each well of a 96-
well, V-bottom plate, followed by the addition of 50 l of CD8+ T cells at a ratio of 10:1. After 4 h of 
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incubation at 37°C, 50 l of supernatant from each well was transferred to miniature vials, and 
radioactivity was determined by a Beckman scintillation counter (PerkinElmer). The percentage of 
specific lysis was calculated using the standard formula [(experimental - spontaneous release)/(total - 
spontaneous release) x 100] and expressed as the mean of triplicate samples. 
 
Western blot 
Snap-frozen tumor samples were homogenized in radio immunoprecipitation assay buffer with 
cOmpleteTM Protease Inhibitor Cocktail Tablets (Roche) and phosphatase inhibitor cocktail (Thermo 
Fisher Scientific), and lysis was performed on ice for 30 min. Cell lysates were centrifuged for 15 min at 
12,000 x g at 4°C. After centrifugation, the supernatant was mixed with 4x loading buffer plus 2.5% of -
mercaptoethanol and loaded on 8% SDS/PAGE gels. Protein bands were transferred to PVDF membranes 
(Bio-RAD) at 90 V for 2 h in a Bio-Rad Mini Trans-Blot system. The membrane was incubated 
sequentially with different primary antibodies: anti-p65, anti-p-p65, anti-p-STAT1, anti-p-STAT3, and 
anti-STAT3 (all from Cell Signaling Technology), and anti-STAT1 and anti-beta-Actin (from Santa Cruz 
Biotechnology, Dallas, Tx). Secondary antibodies were from LI-COR, (Lincoln, NE). Protein detection 
was performed using the Odyssey imaging system (LI-COR). 
 
ELISA 
Conditioned medium from Ccr2+/+ and Ccr2-/- cancer cells was collected, and GM-CSF concentration was 
evaluated by ELISA, following the manufacturer’s instructions (R&D Systems). Briefly, 50 µl of cytokine 
standard or conditioned medium was added to the wells of the pre-coated ELISA plate and incubated at 
room temperature for 2 h. Plates were washed five times with wash buffer and incubated with a horseradish 
peroxidase-linked polyclonal antibody specific to mouse GM-CSF for 2 h, followed by incubation with 
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substrate solution for 30 min. After adding 100 μL of stop solution, the optical density of each well was 
measured at 450 nm using a microplate reader. The concentrations of GM-CSF in the conditioned medium 
were calculated according to the standard curve. 
 
Whole mount carmine staining of mammary glands 
Mammary glands were isolated and spread out on glass slides. Then, the mammary glands were fixed in 
Carnoy’s fixative (60% ethanol, 30% chloroform, and 10% glacial acetic acid) for 2–4 hours at room 
temperature, followed by 15-minute washes first in 70% and then in 50% ethanol, with a final rinse in 
double-distilled water. The glands were then stained with carmine red stain (2.5 g of aluminum potassium 
sulfate, 1 g of carmine, and dH2O to a final volume of 500 mL, boiled for 25 min) for 16 hours or until 
the fat pad was a uniform pink color. After staining, the mammary glands were de-stained in 1% solution 
of 1N HCl in 70% ethanol. De-stained glands were rinsed twice for 15 min in 70% ethanol followed by 
15-minute washes in first in 90% and then in 100% ethanol. The mammary glands were then placed in 
xylene for two hours for clearing and mounted. 
 
Statistical analysis 
All statistical analyses were performed using GraphPad Prism Version 6 software. Data were analyzed 
using Kaplan-Meier survival analysis, Student’s t-tests, ANOVA, two-way ANOVA, chi-Square test, and 
log-rank (Mantel-Cox) test, as indicated in the figure legends, with an alpha of 0.05. The number of 
sampled units, N, is indicated in the figure legends.  
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CCL2:  C-C chemokine ligand 2 
CCR2:  C-C chemokine receptor type 2 
chOVA:  mCherry-ovalbumin 
CTL:  cytotoxic T lymphocyte 
DC:  dendritic cell 
dLN: draining lymph node 
FISH: Fluorescence in situ hybridization 
G-CSF granulocyte colony-stimulating factor 
GM-CSF:  granulocyte-macrophage colony-stimulating factor 
IACUC: Institutional Animal Care and Use Committee 
ISH: in situ hybridization 
IFN-γ:  interferon gamma 
LAMP-1:  lysosomal-associated membrane protein 1 
MDSC:  myeloid-derived suppressor cell 
MHC:  major histocompatibility complex 
MMTV:  mouse mammary tumor virus 
PD-L1:  programmed cell death ligand 1 
PFA:  paraformaldehyde 
PyMT:  polyoma middle T 
RPKM: reads per kilobase million 
RPMI:        Roswell Park Memorial Institute  
TCGA:  The Cancer Genome Atlas 
TCR:  T cell receptor 
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TUNEL:    terminal deoxynucleotidyl transferase dUTP nick end labeling 
.CC-BY-NC-ND 4.0 International licenseunder a
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available 
The copyright holder for this preprint (which wasthis version posted December 27, 2019. ; https://doi.org/10.1101/390187doi: bioRxiv preprint 
Fein et al. 
	 Page 36
REFERENCES 	
Ahn, R., V. Sabourin, A.M. Bolt, S. Hebert, S. Totten, N. De Jay, M.C. Festa, Y.K. Young, Y.K. Im, T. 
Pawson, A.E. Koromilas, W.J. Muller, K.K. Mann, C.L. Kleinman, and J. Ursini-Siegel. 2017. The Shc1 
adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. 
Nat Commun 8:14638. 
Anders, S., P.T. Pyl, and W. Huber. 2015. HTSeq--a Python framework to work with high-throughput 
sequencing data. Bioinformatics 31:166-169. 
Bayne, L.J., G.L. Beatty, N. Jhala, C.E. Clark, A.D. Rhim, B.Z. Stanger, and R.H. Vonderheide. 2012. 
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T 
cell immunity in pancreatic cancer. Cancer Cell 21:822-835. 
Bonapace, L., M.M. Coissieux, J. Wyckoff, K.D. Mertz, Z. Varga, T. Junt, and M. Bentires-Alj. 2014. 
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 
515:130-133. 
Boring, L., J. Gosling, S.W. Chensue, S.L. Kunkel, R.V. Farese, Jr., H.E. Broxmeyer, and I.F. Charo. 
1997. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine 
receptor 2 knockout mice. J Clin Invest 100:2552-2561. 
Broz, M.L., M. Binnewies, B. Boldajipour, A.E. Nelson, J.L. Pollack, D.J. Erle, A. Barczak, M.D. 
Rosenblum, A. Daud, D.L. Barber, S. Amigorena, L.J. Van't Veer, A.I. Sperling, D.M. Wolf, and M.F. 
Krummel. 2014. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting 
cells critical for T cell immunity. Cancer Cell 26:638-652. 
Chen, J., C.C. Jiang, L. Jin, and X.D. Zhang. 2016a. Regulation of PD-L1: a novel role of pro-survival 
signalling in cancer. Ann Oncol 27:409-416. 
Chen, W., Q. Gao, S. Han, F. Pan, and W. Fan. 2015. The CCL2/CCR2 axis enhances IL-6-induced 
epithelial-mesenchymal transition by cooperatively activating STAT3-Twist signaling. Tumour Biol 
36:973-981. 
Chen, X., Y. Wang, D. Nelson, S. Tian, E. Mulvey, B. Patel, I. Conti, J. Jaen, and B.J. Rollins. 2016b. 
CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in 
Mice. PLoS One 11:e0165595. 
de Mingo Pulido, A., A. Gardner, S. Hiebler, H. Soliman, H.S. Rugo, M.F. Krummel, L.M. Coussens, and 
B. Ruffell. 2018. TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in 
Breast Cancer. Cancer Cell 33:60-74 e66. 
.CC-BY-NC-ND 4.0 International licenseunder a
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available 
The copyright holder for this preprint (which wasthis version posted December 27, 2019. ; https://doi.org/10.1101/390187doi: bioRxiv preprint 
Fein et al. 
	 Page 37
Deshmane, S.L., S. Kremlev, S. Amini, and B.E. Sawaya. 2009. Monocyte chemoattractant protein-1 
(MCP-1): an overview. J Interferon Cytokine Res 29:313-326. 
Dobin, A., C.A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. Chaisson, and T.R. 
Gingeras. 2013. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15-21. 
Dunn, G.P., A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber. 2002. Cancer immunoediting: from 
immunosurveillance to tumor escape. Nat Immunol 3:991-998. 
Dunn, G.P., L.J. Old, and R.D. Schreiber. 2004. The three Es of cancer immunoediting. Annu Rev Immunol 
22:329-360. 
Eden, E., R. Navon, I. Steinfeld, D. Lipson, and Z. Yakhini. 2009. GOrilla: a tool for discovery and 
visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10:48. 
Engelhardt, J.J., B. Boldajipour, P. Beemiller, P. Pandurangi, C. Sorensen, Z. Werb, M. Egeblad, and M.F. 
Krummel. 2012. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens 
and stably engage tumor-specific T cells. Cancer Cell 21:402-417. 
Fang, W.B., I. Jokar, A. Zou, D. Lambert, P. Dendukuri, and N. Cheng. 2012. CCL2/CCR2 chemokine 
signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 
mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem 287:36593-36608. 
Freeman, G.J., A.J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L.J. Fitz, N. Malenkovich, T. 
Okazaki, M.C. Byrne, H.F. Horton, L. Fouser, L. Carter, V. Ling, M.R. Bowman, B.M. Carreno, M. 
Collins, C.R. Wood, and T. Honjo. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel 
B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034. 
Garrido, F., I. Romero, N. Aptsiauri, and A.M. Garcia-Lora. 2016. Generation of MHC class I diversity 
in primary tumors and selection of the malignant phenotype. Int J Cancer 138:271-280. 
Greter, M., J. Helft, A. Chow, D. Hashimoto, A. Mortha, J. Agudo-Cantero, M. Bogunovic, E.L. Gautier, 
J. Miller, M. Leboeuf, G. Lu, C. Aloman, B.D. Brown, J.W. Pollard, H. Xiong, G.J. Randolph, J.E. 
Chipuk, P.S. Frenette, and M. Merad. 2012. GM-CSF controls nonlymphoid tissue dendritic cell 
homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 36:1031-
1046. 
Guy, C.T., R.D. Cardiff, and W.J. Muller. 1992. Induction of mammary tumors by expression of 
polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954-
961. 
Hildner, K., B.T. Edelson, W.E. Purtha, M. Diamond, H. Matsushita, M. Kohyama, B. Calderon, B.U. 
Schraml, E.R. Unanue, M.S. Diamond, R.D. Schreiber, T.L. Murphy, and K.M. Murphy. 2008. Batf3 
.CC-BY-NC-ND 4.0 International licenseunder a
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available 
The copyright holder for this preprint (which wasthis version posted December 27, 2019. ; https://doi.org/10.1101/390187doi: bioRxiv preprint 
Fein et al. 
	 Page 38
deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 
322:1097-1100. 
Hu, Q., M. Myers, W. Fang, M. Yao, G. Brummer, J. Hawj, C. Smart, C. Berkland, and N. Cheng. 2019. 
Role of ALDH1A1 and HTRA2 expression in CCL2/CCR2-mediated breast cancer cell growth and 
invasion. Biol Open 8: bio040873 
Igney, F.H., and P.H. Krammer. 2002. Immune escape of tumors: apoptosis resistance and tumor 
counterattack. J Leukoc Biol 71:907-920. 
Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R.M. Steinman. 
1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented 
with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693-1702. 
Izumi, K., L.Y. Fang, A. Mizokami, M. Namiki, L. Li, W.J. Lin, and C. Chang. 2013. Targeting the 
androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage 
recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med 5:1383-1401. 
Jones, L.M., M.L. Broz, J.J. Ranger, J. Ozcelik, R. Ahn, D. Zuo, J. Ursini-Siegel, M.T. Hallett, M. 
Krummel, and W.J. Muller. 2016. STAT3 Establishes an Immunosuppressive Microenvironment during 
the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. Cancer Res 76:1416-
1428. 
Labovsky, V., L.M. Martinez, K.M. Davies, M. de Lujan Calcagno, H. Garcia-Rivello, A. Wernicke, L. 
Feldman, A. Matas, M.B. Giorello, F.R. Borzone, H. Choi, S.C. Howard, and N.A. Chasseing. 2017. 
Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with 
early breast cancer. BMC Cancer 17:280. 
Lebrecht, A., C. Grimm, T. Lantzsch, E. Ludwig, L. Hefler, E. Ulbrich, and H. Koelbl. 2004. Monocyte 
chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol 25:14-17. 
Lebrecht, A., L. Hefler, C. Tempfer, and H. Koelbl. 2001. Serum cytokine concentrations in patients with 
cervical cancer: interleukin-4, interferon-gamma, and monocyte chemoattractant protein-1. Gynecol 
Oncol 83:170-171. 
Li, M., D.A. Knight, A.S. L, M.J. Smyth, and T.J. Stewart. 2013. A role for CCL2 in both tumor 
progression and immunosurveillance. Oncoimmunology 2:e25474. 
Lim, S.Y., A.E. Yuzhalin, A.N. Gordon-Weeks, and R.J. Muschel. 2016. Targeting the CCL2-CCR2 
signaling axis in cancer metastasis. Oncotarget 7: 28697–28710. 
.CC-BY-NC-ND 4.0 International licenseunder a
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available 
The copyright holder for this preprint (which wasthis version posted December 27, 2019. ; https://doi.org/10.1101/390187doi: bioRxiv preprint 
Fein et al. 
	 Page 39
Lin, E.Y., J.G. Jones, P. Li, L. Zhu, K.D. Whitney, W.J. Muller, and J.W. Pollard. 2003. Progression to 
malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model 
for human diseases. Am J Pathol 163:2113-2126. 
Love, M.I., W. Huber, and S. Anders. 2014. Moderated estimation of fold change and dispersion for RNA-
seq data with DESeq2. Genome Biol 15:550. 
Lu, Y., Z. Cai, D.L. Galson, G. Xiao, Y. Liu, D.E. George, M.F. Melhem, Z. Yao, and J. Zhang. 2006. 
Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer 
growth and invasion. Prostate 66:1311-1318. 
Mayer, C.T., P. Ghorbani, A. Nandan, M. Dudek, C. Arnold-Schrauf, C. Hesse, L. Berod, P. Stuve, F. 
Puttur, M. Merad, and T. Sparwasser. 2014. Selective and efficient generation of functional Batf3-
dependent CD103+ dendritic cells from mouse bone marrow. Blood 124:3081-3091. 
Mehta, H.M., M. Malandra, and S.J. Corey. 2015. G-CSF and GM-CSF in Neutropenia. J Immunol 
195:1341-1349. 
Meyer, M.A., J.M. Baer, B.L. Knolhoff, T.M. Nywening, R.Z. Panni, X. Su, K.N. Weilbaecher, W.G. 
Hawkins, C. Ma, R.C. Fields, D.C. Linehan, G.A. Challen, R. Faccio, R.L. Aft, and D.G. DeNardo. 2018. 
Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune 
surveillance. Nat Commun 9:1250. 
Mitchell, L.A., R.J. Hansen, A.J. Beaupre, D.L. Gustafson, and S.W. Dow. 2013. Optimized dosing of a 
CCR2 antagonist for amplification of vaccine immunity. Int Immunopharmacol 15:357-363. 
Muller, A., B. Homey, H. Soto, N. Ge, D. Catron, M.E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, 
S.N. Wagner, J.L. Barrera, A. Mohar, E. Verastegui, and A. Zlotnik. 2001. Involvement of chemokine 
receptors in breast cancer metastasis. Nature 410:50-56. 
Nakasone, E.S., H.A. Askautrud, T. Kees, J.H. Park, V. Plaks, A.J. Ewald, M. Fein, M.G. Rasch, Y.X. 
Tan, J. Qiu, J. Park, P. Sinha, M.J. Bissell, E. Frengen, Z. Werb, and M. Egeblad. 2012. Imaging tumor-
stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. 
Cancer Cell 21:488-503. 
Nielsen, B.S., L.R. Lund, I.J. Christensen, M. Johnsen, P.A. Usher, L. Wulf-Andersen, T.L. Frandsen, K. 
Dano, and H.J. Gundersen. 2001. A precise and efficient stereological method for determining murine 
lung metastasis volumes. Am J Pathol 158:1997-2003. 
Nywening, T.M., A. Wang-Gillam, D.E. Sanford, B.A. Belt, R.Z. Panni, B.M. Cusworth, A.T. Toriola, 
R.K. Nieman, L.A. Worley, M. Yano, K.J. Fowler, A.C. Lockhart, R. Suresh, B.R. Tan, K.H. Lim, R.C. 
Fields, S.M. Strasberg, W.G. Hawkins, D.G. DeNardo, S.P. Goedegebuure, and D.C. Linehan. 2016. 
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in 
.CC-BY-NC-ND 4.0 International licenseunder a
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available 
The copyright holder for this preprint (which wasthis version posted December 27, 2019. ; https://doi.org/10.1101/390187doi: bioRxiv preprint 
Fein et al. 
	 Page 40
patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, 
dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17:651-662. 
Pylayeva-Gupta, Y., K.E. Lee, C.H. Hajdu, G. Miller, and D. Bar-Sagi. 2012. Oncogenic Kras-induced 
GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21:836-847. 
Qian, B., Y. Deng, J.H. Im, R.J. Muschel, Y. Zou, J. Li, R.A. Lang, and J.W. Pollard. 2009. A distinct 
macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. 
PLoS One 4:e6562. 
Qian, B.Z., J. Li, H. Zhang, T. Kitamura, J. Zhang, L.R. Campion, E.A. Kaiser, L.A. Snyder, and J.W. 
Pollard. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 
475:222-225. 
Roberts, E.W., M.L. Broz, M. Binnewies, M.B. Headley, A.E. Nelson, D.M. Wolf, T. Kaisho, D. 
Bogunovic, N. Bhardwaj, and M.F. Krummel. 2016. Critical Role for CD103(+)/CD141(+) Dendritic 
Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. 
Cancer Cell 30:324-336. 
Rodriguez-Frade, J.M., A.J. Vila-Coro, A.M. de Ana, J.P. Albar, A.C. Martinez, and M. Mellado. 1999. 
The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization 
of its receptor CCR2. Proc Natl Acad Sci U S A 96:3628-3633. 
Ruffell, B., D. Chang-Strachan, V. Chan, A. Rosenbusch, C.M. Ho, N. Pryer, D. Daniel, E.S. Hwang, H.S. 
Rugo, and L.M. Coussens. 2014. Macrophage IL-10 blocks CD8+ T cell-dependent responses to 
chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26:623-637. 
Sherwood, A.M., R.O. Emerson, D. Scherer, N. Habermann, K. Buck, J. Staffa, C. Desmarais, N. Halama, 
D. Jaeger, P. Schirmacher, E. Herpel, M. Kloor, A. Ulrich, M. Schneider, C.M. Ulrich, and H. Robins. 
2013. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences 
that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother  62:1453-1461. 
Soria, G., and A. Ben-Baruch. 2008. The inflammatory chemokines CCL2 and CCL5 in breast cancer. 
Cancer Lett 267:271-285. 
Spranger, S., D. Dai, B. Horton, and T.F. Gajewski. 2017. Tumor-Residing Batf3 Dendritic Cells Are 
Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell 31:711-723 e714. 
Subramanian, A., P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. 
Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov. 2005. Gene set enrichment analysis: a knowledge-
based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-
15550. 
.CC-BY-NC-ND 4.0 International licenseunder a
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available 
The copyright holder for this preprint (which wasthis version posted December 27, 2019. ; https://doi.org/10.1101/390187doi: bioRxiv preprint 
Fein et al. 
	 Page 41
Winograd, R., K.T. Byrne, R.A. Evans, P.M. Odorizzi, A.R. Meyer, D.L. Bajor, C. Clendenin, B.Z. 
Stanger, E.E. Furth, E.J. Wherry, and R.H. Vonderheide. 2015. Induction of T-cell Immunity Overcomes 
Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. 
Cancer Immunol Res 3:399-411. 
Wolf, M.J., A. Hoos, J. Bauer, S. Boettcher, M. Knust, A. Weber, N. Simonavicius, C. Schneider, M. 
Lang, M. Sturzl, R.S. Croner, A. Konrad, M.G. Manz, H. Moch, A. Aguzzi, G. van Loo, M. Pasparakis, 
M. Prinz, L. Borsig, and M. Heikenwalder. 2012. Endothelial CCR2 Signaling Induced by Colon 





.CC-BY-NC-ND 4.0 International licenseunder a
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available 
The copyright holder for this preprint (which wasthis version posted December 27, 2019. ; https://doi.org/10.1101/390187doi: bioRxiv preprint 
Fein et al. 
	 Page 42
FIGURE LEGENDS 
Fig. 1: Cancer cell Ccr2 promotes primary tumor growth, reducing overall survival 
a. Tumor onset (tumor-free survival) is similar for MMTV-PyMT;Ccr2+/+, MMTV-PyMT;Ccr2+/-, and 
MMTV-PyMT;Ccr2-/- mice, as determined by weekly palpation and caliper measurement. 
N.S.=non-significant (Log-rank [Mantel-Cox] test; n=28 MMTV-PyMT;Ccr2+/+, 20 MMTV-
PyMT;Ccr2+/-, and 18 MMTV-PyMT;Ccr2-/- mice).  
b. Primary tumor growth is reduced in MMTV-PyMT;Ccr2+/- and MMTV-PyMT;Ccr2-/- mice 
compared to MMTV-PyMT;Ccr2+/+ mice, as determined by weekly caliper measurement (mean +/- 
SEM, two-way ANOVA; n=21 MMTV-PyMT;Ccr2+/+, 25 MMTV-PyMT;Ccr2+/-, and 18 MMTV-
PyMT;Ccr2-/- mice).  
c. Time until IACUC-approved endpoint was increased for MMTV-PyMT;Ccr2+/- and MMTV-
PyMT;Ccr2-/- mice compared to MMTV-PyMT;Ccr2+/+ mice (Log-rank [Mantel-Cox] test; n=30 
MMTV-PyMT;Ccr2+/+, 35 MMTV-PyMT;Ccr2+/-, and 29 MMTV-PyMT;Ccr2-/- mice). 
d. Cancer cells express CCR2 (arrows) as determined by RNA in situ hybridization for Ccr2 performed 
on paraffin-embedded tumor sections from MMTV-PyMT;Ccr2+/+ mice. Image is representative of 
more than 10 mice. Scale bar=20 m. 
e. CCR2 is expressed on epithelial cells, as determined by flow cytometry performed on Ccr2+/+ or 
Ccr2-/- tumors transplanted to C57BL/6 hosts. Anti-CCR2 primary antibody was gated on EpCAM+ 
cells and compared to background levels. Left panel shows one representative experiment and right 
panel depicts median fluorescence intensity for all experiments (mean +/- SEM, Student’s t-test; 
n=5). 
f. Schematic of transplantation experiments.  
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g. Primary tumor growth of Ccr2-/- cancer cells is reduced compared to that of Ccr2+/+ cancer cells 
regardless of the Ccr2 genotype of the host, as determined by weekly caliper measurement (mean 
+/- SEM, two-way ANOVA; n=8 for all conditions). 
h. Survival until IACUC-defined endpoint is increased in mice bearing Ccr2-/- cancer cells regardless 
of the genotype of the host (Log-rank [Mantel-Cox] test; n=8 for all conditions).  
 
Fig. 2: Loss of Ccr2 increases apoptosis in vivo with no effect on proliferation 
a. Four representative photomicrographs of H&E-stained tumors derived from Ccr2+/+ and Ccr2-/- 
cancer cells. Arrows denote cystic areas; also note lipid vacuoles in tumors from Ccr2-/- cancer cells 
(Scale bar=100 m). 
b. Histology score of solid area in tumors from Ccr2+/+ and Ccr2-/- transplants (mean +/- SEM, 
Student’s t-test; n=10 in Ccr2+/+ and n=8 in Ccr2-/-).  
c. Proliferation is unchanged between Ccr2+/+ and Ccr2-/- tumor transplants during the growth-restricted 
phase, as determined by Ki67-positive nuclear stain. Left panels are representative 
photomicrographs (Scale bar=100 m), and right panel shows quantification (mean +/- SEM, 
Student’s t-test; n=10 and 9 for Ccr2+/+ and Ccr2-/- transplants, respectively). 
d. Proliferation is unchanged in Ccr2+/+ and Ccr2-/- cancer cells in vitro during the growth-restricted 
phase, as determined by absorbance after 24 h using CellTiter 96 AQueous One Solution Cell 
Proliferation (MTS) Assay (mean +/- SEM, Student’s t-test; n=4). 
e. Ccr2-/- cancer cells have an increased apoptotic index compared to Ccr2-/- cancer cells during the 
growth-restricted phase, as determined by double immune staining for PyMT and cleaved caspase-
3. Left panels are representative photomicrographs, with arrows indicating apoptotic cancer cells 
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(Scale bar=100 m); right panel shows quantification (mean +/- SEM, Student’s t-test; n=5). Each 
dot represents an average of five random fields of views from one tumor.  
f.  Ccr2-/- cancer cells are less viable than Ccr2+/+ cancer cells in serum-free conditions, as determined 
by absorbance in MTS assay after serum starvation for 24 h (mean +/- SEM, Student’s t-test; n=3). 
 
Fig. 3: Ccr2-/- cancer cells have increased expression of interferon (IFN) response genes and of genes 
involved in MHC class I antigen presentation 
a. A hierarchically clustered heat map of Ccr2+/+ and Ccr2-/- cancer cell samples, collected during 
the growth-restricted phase, based on expression levels of select genes associated with antigen 
processing and presentation, as well as epithelial-to-mesenchymal transition (n=3 for Ccr2+/+ and 
Ccr2-/- tumors). 
b. Gene set enrichment analysis plots showing enrichment of IFN- response and luminal gene set 
expression in Ccr2-/- cancer cells (NES=normalized enrichment score) 
c. Gene ontology (GO) term enrichment plots showing the most significantly overrepresented GO 
terms in Ccr2-/- cancer cells compared to Ccr2+/+ cancer cells. 
 
Fig. 4: Tumors derived from Ccr2-/- cancer cells have increased infiltration of activated CTLs 
a. Tumors from Ccr2-/- cancer cells have fewer CD4+ T cells and more CD8+ T cells during the 
growth-restricted phase, as determined by flow cytometry gated on CD45+CD3+ cells. Left panels 
are representative examples of dot plots, and right panels show quantification of CD4+ and CD8+ 
cells (mean +/- SEM, Student’s t-test; n=5).  
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b. Representative immunofluorescence staining showing that more CD8a+ T cells (red) infiltrate into 
tumors derived from Ccr2-/- cancer cells than tumors from Ccr2+/+ cancer cells during the growth-
restricted phase (Scale bars=100 m).  
c. Quantification of CD8a+ T cells in the tumors (mean +/- SEM, Student’s t-test; n=5 tumors. Each 
dot represents the average of five random fields of views of one tumor).  
d. PD-1 levels were increased in CD8+ T cells in tumors from Ccr2-/- cancer cells during the growth-
restricted phase, as determined by flow cytometry gating on CD45+CD3+CD8+ cells (mean +/- 
SEM, Student’s t-test; n=5). 
e. LAMP-1 (CD107a) levels were increased in CD8+ T cells in Ccr2-/- tumors during the growth-
restricted phase, as determined by flow cytometry gated on CD45+CD3+CD8+ cells (mean +/- SEM, 
Student’s t-test; n=4 and 5 for Ccr2+/+ and Ccr2-/- transplants, respectively). 
f. Intracellular granzyme B levels were decreased in CD8+ T cells in Ccr2-/- tumors during the growth-
restricted phase, as determined by flow cytometry gated on CD45+CD3+CD8+ cells, after 2 h of 
incubation with Brefeldin A (mean +/- SEM, Student’s t-test; n=5). 
 
Fig. 5: Cancer cell Ccr2 tumor growth requires functional adaptive immunity  
a. Schematic of experimental design.  
b. Tumors from Ccr2+/+ cancer cells grow faster than tumors from Ccr2-/- cancer cells in mice with 
intact immune systems. Tumor burden was determined by weekly caliper measurement. Mice were 
sacrificed at IACUC-approved endpoint (mean +/- SEM, two-way ANOVA; n=20 per condition).  
c. Tumors from Ccr2+/+ cancer cells grow similarly to tumors from Ccr2-/- cancer cells in athymic host 
mice. Tumor burden was determined by weekly caliper measurement. Mice were sacrificed at 
IACUC-approved endpoint (mean +/- SEM, two-way ANOVA; n=20 per condition). 
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d. Apoptosis was unchanged between Ccr2+/+ and Ccr2-/- transplants to athymic hosts, as determined 
by TUNEL stain. Left panels are representative photomicrographs (Scale bar=100 m), with arrows 
pointing to apoptotic cells; right panel shows quantification (mean +/- SEM, Student’s t-test; n=8 
and 6 for Ccr2+/+ and Ccr2-/- transplants, respectively). 
e. Representative H&E staining of transplanted tumors from Ccr2+/+ and Ccr2-/- cancer cells to nude 
hosts. Arrows indicate highly necrotic areas (Scale bar=100 m). 
f. Histology score of solid area of transplanted tumors from Ccr2+/+ and Ccr2-/- cancer cells to athymic 
hosts (mean +/- SEM, Student’s t-test; n=10 in Ccr2+/+ and n=9 in Ccr2-/-). 
 
Fig. 6: Cancer cell Ccr2 signaling protects against T cell-mediated killing 
a. Primary tumor growth is reduced in MMTV-PyMT-chOVA;Ccr2-/- mice compared to MMTV-
PyMT;Ccr2+/+ mice, as determined by weekly caliper measurement once the tumors were palpable 
(mean +/- SEM, two-way ANOVA; n=6 MMTV-PyMT;Ccr2+/+, and n=5 MMTV-PyMT;Ccr2-/- 
mice).  
b. Ccr2-/- cancer cells are more sensitive to T cell cytotoxicity than Ccr2+/+ cancer cells. Cytotoxicity 
of CD8+ OT-1 T cells toward MMTV-PyMT-chOVA;Ccr2+/+ or MMTV-PyMT-chOVA;Ccr2-/- 
primary cancer cells, with or without OVA peptides, measured by chromium (Cr51) release (mean 
+/- SEM, Student’s t-test; n=3).  
c. Inhibiting CCR2 increased T cell cytotoxicity against Ccr2+/+ cancer cells. Cytotoxicity of CD8+ 
OT-1 T cells toward MMTV-PyMT-chOVA;Ccr2+/+ or MMTV-PyMT-chOVA;Ccr2-/- cancer cells, 
with or without CCR2 inhibitor, measured by chromium (Cr51) release (mean +/- SEM, Student’s t-
test; each dot is the average of triplicate from an independent experiment. n=4 and 3 for MMTV-
PyMT-chOVA;Ccr2+/+ and MMTV-PyMT-chOVA;Ccr2-/- cancer cells, respectively). 
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d. Model of clonality measured by T cell receptor (TCR) sequencing. 
e. Productive clonality in tumors from Ccr2+/+ and Ccr2-/- cancer cells (mean +/- SEM, Student’s t-
test; n=4). 
f. Productive clonality in spleens was unchanged between Ccr2+/+ and Ccr2-/- tumors (mean +/- SEM, 
Student’s t-test; n=4). 
 
Fig. 7: Localized STAT1 activation in Ccr2-/- tumors 
a. Comparison of STAT1 activation in tumors from Ccr2+/+ or Ccr2-/- cancer cells during the growth-
restricted phase, by Western blot analysis (left). Each lane contains a protein sample from a tumor 
from a different mouse. Quantifications of protein expression normalized to -actin levels (right) 
(mean +/- SEM, n=4 for Ccr2+/+, n=5 for Ccr2-/-). 
b. Representative photomicrographs of p-STAT1 (top) and p-STAT3 (bottom) staining in sections of 
tumors from Ccr2+/+ or Ccr2-/- cancer cells. Scale bar=100 m.  
c. Quantification of the immunohistochemical staining in (b), using H-score, shows higher STAT1 
phosphorylation in tumors from Ccr2-/- than from Ccr2+/+ cancer cells, but similar levels of STAT3 
phosphorylation (mean +/- SEM, Student’s t-test; n= 5). 
 
Fig. 8: MHC class I expression is reduced and PD-L1 expression increased in Ccr2+/+ cancer cells in 
immunocompetent mice 
a. MHC class I expression is increased in MMTV-PyMT-chOVA;Ccr2-/- tumors compared to 
MMTV-PyMT-chOVA;Ccr2+/+ tumors during the growth-restricted phase, as determined by 
immunofluorescence staining (upper panels: representative images; Scale bar=50 m) and by flow 
.CC-BY-NC-ND 4.0 International licenseunder a
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available 
The copyright holder for this preprint (which wasthis version posted December 27, 2019. ; https://doi.org/10.1101/390187doi: bioRxiv preprint 
Fein et al. 
	 Page 48
cytometry (bottom panel), gated on EpCAM+, mCherry+ cells (mean +/- SEM, Student’s t-test; 
n=8 and 4 for PyMT-chOVA;Ccr2+/+ and PyMT-chOVA;Ccr2-/- tumors, respectively). 
b. MHC class I is increased on Ccr2-/- compared to Ccr2+/+ cancer cells after transplantation into 
C57BL/6 hosts during the growth-restricted phase, as determined by immunofluorescence staining 
(upper panels; Scale bar=50 m). Quantification of mean pixel count (bottom panel, mean +/- 
SEM, Student’s t-test; n= 5). 
c. MHC class I is unchanged on Ccr2+/+ and Ccr2-/- cancer cells transplants to athymic hosts, as 
determined by immunofluorescence staining (upper panels; Scale bar=50 m). Quantification of 
mean pixel count (bottom panel, mean +/- SEM, Student’s t-test; n=4 and 5 for Ccr2+/+ and Ccr2-
/- transplants, respectively). 
d. PD-L1 is decreased on Ccr2-/- cancer cells, as determined by flow cytometry gated on EpCAM+ 
cells (mean +/- SEM, Student’s t-test; n=5).  
e. PD-L1 mRNA levels are decreased in cultured Ccr2-/- cancer cells, but the cells respond equally 
well to IFN-γ treatment as Ccr2-/- cancer cells, as determined by qPCR. Ccr2+/+ and Ccr2-/- cancer 
cells growing in culture were treated with either 0, 0.2, 2.0, or 20 ng/mL of recombinant IFN-γ for 
48 h (mean +/- SEM, Student’s t-test; n=3).  
f. Treatment with four intraperitoneal doses of anti-PD-L1 antibody (200 g/injection) had no 
significant effect on growth of Ccr2+/+ or Ccr2-/- tumors in vivo, compared to control rat IgG 
antibody (arrows indicate treatments; mean +/- SEM, two-way ANOVA; n=20 tumors for all 
conditions). 
 
Fig. 9: Ccr2-/- tumors promote infiltration and activation of cross-presenting CD103+ DCs 
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a. Representative immunofluorescence images showing that more CD11c+ dendritic cells (red) 
infiltrate into Ccr2-/- tumors compared to Ccr2+/+ tumors during the growth-restricted phase 
(EpCAM+, green; Scale bar=100 m).  
b. CD103+ DCs are increased in Ccr2-/- tumors compared to Ccr2+/+ tumors during the growth-
restricted phase, as determined by flow cytometry gated on CD45+CD11c+MHC class II+ cells. 
SSC=side scatter (mean +/- SEM, Student’s t-test; n=5). 
c. CD103+ DCs are increased in the draining lymph nodes (dLNs) of Ccr2-/- tumors compared to the 
dLNs of Ccr2+/+ tumors during the growth-restricted phase, as determined by flow cytometry gated 
on CD45+CD11c+MHC class II+ cells (mean +/- SEM, Student’s t-test; n=5). 
d. Tumors from transplanted Ccr2-/- cancer cells have increased DC infiltration and elevated markers 
of DC activation compared to tumors from Ccr2+/+ cancer cells. RT-qPCR on tumors during the 
growth-restricted phase (mean +/- SEM, Student’s t-test; for Cd11c, n=6 in Ccr2+/+ and n=8 in 
Ccr2-/-, for other genes, n=5 in Ccr2+/+ and n=6 in Ccr2-/-). 
e. DCs in Ccr2-/- tumors are more activated during the growth-restricted phase, as determined by 
flow cytometry for CD86+ gated on CD45+CD11c+MHC class II+ cells (mean +/- SEM, 
Student’s t-test; n=5). 
f. Flow cytometry on dLNs with or without injection of irradiated cancer cells into the mammary 
gland. Note that CD103+ DCs are only increased in the dLNs of the glands after injection of Ccr2-
/- cancer cells, not in non-dLNs from axillary glands (mean +/- SEM, Student’s t-test; n=5).  
g. CD103+ DCs are decreased in Ccr2-/- tumors compared to Ccr2+/+ tumors in athymic hosts, as 
determined by flow cytometry gated on CD45+CD11c+ cells (mean +/- SEM, Student’s t-test; 
n=5). 
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Fig. 10: Cross-presenting CD103+ DCs are critical for immune control of Ccr2-/- cancer cells	
a. Conditioned medium from Ccr2-/- cancer cells induce similar numbers of CD11c DCs (left), but 
more CD103+ BMDCs (right) in vitro, compared to conditioned medium from Ccr2+/+ cancer cells 
(mean +/- SEM, Student’s t-test; n=3). 
b. Conditioned medium from Ccr2+/+ cancer cells cultured with CCR2 inhibitor induced similar 
numbers of CD11c DCs (left), but more CD103+ BMDCs (right) in vitro than conditioned medium 
from control cells cultured in the absence of the inhibitor medium (mean +/- SEM, Student’s t-
test; n=3). 
c. Tumors from transplanted Ccr2-/- cancer cells have elevated Csf2 mRNA (coding GM-CSF) and 
Flt3l (coding FLT3 ligand), but not Ccl2 or Csf3 compared to tumors from Ccr2+/+ cancer cells. 
RT-qPCR on tumors from transplanted Ccr2+/+ and Ccr2-/- cancer cells during the growth-
restricted phase (mean +/- SEM, Student’s t-test; n=5–6 for Ccr2+/+ tumors and n=6 for Ccr2-/- 
tumors). 
d. Tumor growth is increased in Batf3-/- hosts transplanted with Ccr2-/- cancer cells, as determined by 
weekly caliper measurement (mean +/- SEM, two-way ANOVA; n=9 in Ccr2+/+ to Batf3-/- hosts 
group, and n=10 for the other three groups). 
e. CD103+ DCs are increased in Ccr2-/- tumors compared to Ccr2+/+ tumors in C57BL/6 hosts but 
are low in Batf3-/- hosts (mean +/- SEM, Student’s t-tests; n=5). 
f. CD8a+ T cells are increased in early-stage tumors (three weeks) from transplanted Ccr2-/- cancer 
cells compared to tumors from Ccr2+/+ cancer cells in C57BL/6 hosts, but are low in Batf3-/- hosts 
(mean +/- SEM, Student’s t-tests; n=9–10). 
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g. Lamp-1 (CD107a) and CD8a double-positive T cells are increased in early-stage tumors (three 
weeks) from transplanted Ccr2-/- cancer cells compared to tumors from Ccr2+/+ cancer cells, but 
are low in Batf3-/- hosts (mean +/- SEM, Student’s t-tests; n=9–10). 
h. PD-1 and CD8a double-positive T cells are increased in early-stage tumors (three weeks) from 
transplanted Ccr2-/- cancer cells compared to tumors from Ccr2+/+ cancer cells in C57BL/6 hosts, 
but are low in Batf3-/- hosts (mean +/- SEM, Student’s t-tests; n=5). 
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